Friday, December 30, 2011

Detection of central nervous system tissue as bovine spongiform encephalopathy specified risk material in traditional Turkish meat products, farmers, and sporadic CJD in Turkey

Research Article




Detection of central nervous system tissue as bovine spongiform encephalopathy specified risk material in traditional Turkish meat products



Mehmet Kale1,*,


Sibel Hasırcıoglu1,


Cagdas Ozturk2,


A Selcen Akcan Kale3,


Yusuf Dogruer4


Article first published online: 22 DEC 2011




DOI: 10.1002/jsfa.5527




Copyright © 2011 Society of Chemical Industry




Keywords:CNS;BSE-SRM;Turkish meat products;ELISA



Abstract


BACKGROUND: This study used enzyme-linked immunosorbent assay kits to investigate the presence of central nervous system (CNS) tissue in commercial raw and processed traditional Turkish meat products offered for consumption in various markets.


RESULTS: Ninety-six raw traditional Turkish meat products (32 fresh raw beef patties, 32 cig kofta, 32 pastirma) and 64 processed traditional Turkish meat products (32 doner kebabs and 32 fresh processed beef patties) were analysed. CNS tissue was not found in pastirma, doner kebab, or fresh processed beef patty samples. The levels of CNS contamination in fresh raw beef patties were low (0.1% absorbance standard; 3.1%) and moderate (0.2% absorbance standard; 6.2%). The level of contamination in the cig kofta was low (0.1% absorbance standard; 18.8%).


CONCLUSION: CNS tissue was present in all raw traditional Turkish meat products except for pastirma. Copyright © 2011 Society of Chemical Industry










Greetings,



HMMM,


where did they ship those SRM beef patties too ???


disturbing.


what’s the history with those farmers ???


5 out of 9 sporadic CJD victims farmers ???



another coincidence $$$




From: TSS


Subject: Increased incidence of sporadic CJD on the island of Crete


Date: August 3, 2001 at 7:28 pm PST


Increased incidence of sporadic Creutzfeldt-Jakob disease on the island of Crete associated with a high rate of PRNP 129-methionine homozygosity in the local population


Andreas Plaitakis, MD 1 *, Anna K. Viskadouraki, MD 1, Minas Tzagournissakis, MD 1, Ioannis Zaganas, MD 1, Susan Verghese-Nikolakaki, PhD 2, Vasilis Karagiorgis 2, Ioannis Panagiotides, MD 3, Constantine Kilindireas, MD 4, Eustratios Patsouris, MD 5, Christine Haberler, MD 6, Herbert Budka, MD 6, Theodoros Sklaviadis, PhD 2 1Department of Neurology, Division of Medicine, University of Crete, School of Health Sciences, Heraklion, Crete, Greece 2Laboratory of Pharmacology, Department of Pharmaceutical Sciences, School of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece 3Department of Pathology, Division of Medicine, University of Crete, School of Health Sciences, Heraklion, Crete, Greece 4Department of Neurology, University of Athens, School of Medicine, Athens, Greece 5Department of Pathology, University of Athens, School of Medicine, Athens, Greece 6Institute of Neurology, University of Vienna, Vienna, Austria email: Andreas Plaitakis (plaitakis@med.uoc.gr)




*Correspondence to Andreas Plaitakis, Department of Neurology, University of Crete, School of Health Sciences, Voutes, Heraklion, Crete, Greece


Funded by: General Secretariat of Research and Technology of Greece; Grant Number: YPER-97 Association for the Advancement of Research and Treatment of Neurologic Disorders of Crete Eú Zr


Abstract


Since the spring of 1997, when the Neurology Department of the University Hospital of Crete admitted its first patient, 9 cases (8 neuropathologically confirmed and 1 probable) of sporadic Creutzfeldt-Jakob disease (sCJD) have been recorded. This represents an annual incidence five-fold higher than expected based on the island's population (0.54 million). Molecular analysis of the prion-protein gene (PRNP) showed no mutations in any of the seven CJD cases studied. Five patients (ages 64-88 years) were homozygous for methionine-129 of PRNP and showed the classic sCJD triad (subacute dementia, myoclonus, periodic electroencephalogram). Brains contained Type 1 (unglycosylated 21.5 kDa band) protease-resistant prion protein (PrPres). Two patients (ages 56 and 57 years), both homozygous for valine-129, showed cerebellar ataxia and later dementia not associated with periodic electroencephalogram; brain PrPres was Type 2. Genotyping of 205 Cretan controls showed that methionine-129 homozygosity, a susceptibility factor for sCJD, was significantly higher in this population than in other Caucasian populations (57.0%, n = 205 versus 41.5%, n = 859. These data are the first to relate a high regional incidence rate for sCJD to the distribution of PRNP 129 genotypes in the local population; however, additional factors may be operational.




Received: 11 December 2000; Revised: 3 April 2001; Accepted: 3 April 2001






Distribution of the M129V polymorphism of the prion protein gene in a Turkish population suggests a high risk for Creutzfeldt-Jakob disease


Nihan Erginel-Unaltuna1, Katell Peoc'h2, Evrim Komurcu1, Tufan Tevfik Acuner3, Halim Issever4 and Jean-Louis Laplanche*,2 1Department of Genetics, Institute for Experimental Medical Research, Istanbul University, Istanbul, Turkey; 2Service de Biochimie et Biologie MoleÂculaire, Association Claude Bernard, HoÃpital LariboisieÁre, Paris, France; 33rd Neurology Clinic, Turkish Ministry of Health Bakirkoy Hospital for Psychiatric and Neurological Diseases, Istanbul, Turkey; 4Division of Biostatistics and Demography, Department of Public Health, Istanbul Medical School, Istanbul University, Istanbul, Turkey


A polymorphism (M129V) at codon 129 of the prion protein gene (PRNP) results in either a methionine residue (Met) or a valine residue (Val) and is known to determine susceptibility for the development of sporadic or acquired Creutzfeldt-Jakob disease (CJD). The distributions of M129V genotypes and alleles in various general populations have been reported and there are clear differences between Western Europeans and East Asians. We analysed the coding sequence of the PRNP gene in 100 healthy Turkish subjects to determine whether the distributions of the M129V genotypes and alleles or other PRNP gene variants in the Turkish population differ from those in other normal populations. Three known polymorphisms but no other gene variants were detected in the PRNP coding sequence of the Turkish individuals. Genotype frequencies at codon 129 were 57% Met/Met, 34% Met/Val and 9% Val/Val, with an allele frequency of 0.740 : 0.260 Met:Val. These distributions are considerably different from those reported for other normal populations residing in Western Europe and East Asia, except in Crete. The higher frequency of 129 Met-homozygotes in Turkey than in Western Europe suggests that the Turkish are at greater risk of developing CJD.


European Journal of Human Genetics (2001) 9, 965 ± 968.


Keywords: Creutzfeldt-Jakob disease; prion; gene; PRNP; polymorphism; Turkey; population; genetic


snip...


Consequently, the distributions of the M129V genotypes and alleles in the Turkish population differ considerably from those reported for other normal populations residing in either Western Europe or East Asia, with the notable exception of Cretan natives. A recent report19 found that the high rate of PRNP 129Met homozygosity in Crete was associated with a local increase in the incidence of sporadic CJD. As homozygosity at PRNP codon 129 is a recognized risk factor for sporadic and acquired CJD in Caucasians5,21 and heterozygosity is protective,2 ± 4,21 the higher frequency of 129Met-homozygotes in Turkey than in Western Europe would also suggest that the Turkish are at increased risk of developing CJD.






Increased Incidence of Sporadic Creutzfeldt- Jakob Disease on the Island of Crete Associated with a High Rate of PRNP 129-Methionine Homozygosity in the Local Population


Andreas Plaitakis, MD,1 Anna K. Viskadouraki, MD,1 Minas Tzagournissakis, MD,1 Ioannis Zaganas, MD,1 Susan Verghese-Nikolakaki, PhD,2 Vasilis Karagiorgis,2 Ioannis Panagiotides, MD,3 Constantine Kilindireas, MD,4 Eustratios Patsouris, MD,5 Christine Haberler, MD,6 Herbert Budka, MD,6 and Theodoros Sklaviadis, PhD2


Since the spring of 1997, when the Neurology Department of the University Hospital of Crete admitted its first patient, nine cases (eight neuropathologically confirmed and one probable) of sporadic Creutzfeldt-Jakob disease (sCJD) have been recorded. This represents an annual incidence five-fold higher than expected based on the island’s population (0.54 million). Molecular analysis of the prion-protein gene (PRNP) showed no mutations in any of the seven CJD cases studied. Five patients (ages 64–88 years) were homozygous for methionine-129 of PRNP and showed the classic sCJD triad (subacute dementia, myoclonus, periodic electroencephalogram). Brains contained type 1 (unglycosylated 21.5 kDa band) protease-resistant prion protein (PrPres). Two patients (ages 56 and 57 years), both homozygous for valine-129, showed cerebellar ataxia and later dementia not associated with periodic electroencephalogram; brain PrPres was type 2. Genotyping of 205 Cretan controls showed that methionine-129 homozygosity, a susceptibility factor for sCJD, was significantly higher in this population than in other Caucasian populations (57.0% n 5 205 vs. 41.5% n 5 859, p < 0.0001). These data are the first to relate a high regional incidence rate for sCJD to the distribution of PRNP 129 genotypes in the local population; however, additional factors may be operational.


Ann Neurol 2001;50:227–233


SNIP...


Table 1. Demographic and Clinical Features of Creutzfeldt-Jakob Disease Cases


Number Age (yrs)/ Gender Occupation Presenting Symptoms Neurological Features Hospital Course


1 56/M Electrician Severe gait ataxia, photophobia, nervousness for 2–3 months Profound cerebellar-oculomotor deficits, mild cognitive decline Rapid neurological decline, death in 2 months


2 57/M Post office employee Gait disturbances, mild memory loss for 2 months Cerebellar and extrapyramidal syndrome, mild cognitive decline Rapid neurological decline, death in 2 months


3 76/M Farmer Visual illusions, mental changes for 1 month Profound dementia, mutism, myoclonus, head scratching Rapid decline, coma in 2 months, death in 7 months


4 68/F Farmer Depression, emotional lability for 2 months Profound dementia, visual hallucinations, myoclonus, ataxia Rapid neurological decline, death in 2.5 months


5 88/M Farmer Mental changes for 1 month Profound dementia, visual hallucinations, myoclonus, ataxia Rapid neurological decline, death in 5 weeks


6 81/F Housewife Insomnia, irritability for 1 year, memory loss for 2 months Profound amnesia, myoclonus, akinetic mutism Rapid neurological decline, death in 2 weeks


7 64/M Restaurant owner Dizziness, unsteadiness, mental changes for 1 month Profound dementia, movement disorder, myoclonus, seizures Rapid neurological decline, death in 4 months


8 65/M Farmer Dizziness, gait disturbances, mental changes for 1.5 months Profound dementia, myoclonus, akinetic mutism Rapid neurological decline, death in 2 months


9 65/F Farmer Distorted vision, hallucinations, mental changes for 2 months Profound dementia, myoclonus, hypertonus, visual hallucinations Rapid neurological decline, death in 2 weeks


SNIP...


Discussion


During the past three and a half years, the annual incidence of sCJD on Crete was 4.76 cases per million. This is about five times greater than annual mortality rates recorded in recent years in several European countries as well as the United States. Although the population of Crete has a high life expectancy,12 this does not appear to be a major factor since age-specific and age-adjusted incidence rates were four- to ten-fold greater than reported elsewhere. To our knowledge, CJD had not been previously recorded on Crete, but a Neurology Department did not exist on the island until 1997. Hence, it is unclear if the epidemiology of the disease has changed recently in this region. Because the reporting period is relatively short, long-term data are needed to see whether the incidence rates recorded here persist or change over more extended periods of observation.


The increased incidence of CJD on Crete is not due to familial cases of the disease in the island’s population. None of our cases had a positive family history, and analysis of the coding region of the PRNP failed to detect mutations associated with familial CJD. We cannot exclude the possibility of DNA changes outside of the coding region of the PRNP studied here, but no such changes predisposing to CJD are currently known.


known. We observed two distinct phenotypes of CJD. The first was seen in seven patients, 64–88 years of age, who showed the classic sCJD triad of rapidly advancing dementia, myoclonic jerks, and periodic sharp waves on EEG. Five of these were tested and found to be homozygous for Met129 of PRNP. Brains showed accumulation of type 1 PrPres (unglycosylated 21.5 kDa band), as defined by Parchi et al.10 The second phenotype was seen in two patients, 55 and 57 years of age, who showed cerebellar ataxia and later dementia in the absence of periodic EEG changes. Both were homozygous for Val129 and their PrPres (unglycosylated band 21.5 kDa)10 was type 2. These findings are in accordance with those of recent reports13,14 showing that codon 129 polymorphism influences the clinical expression of sCJD.




snip... see full text ;






Case Report Creutzfeldt-Jacob Disease: a case report Eren Gozke1,2*, Nursel Erdal1,2 and Muge Unal1,2


* Corresponding author: Eren Gozke erengozke@superonline.com


Author Affiliations


1 Department of Neurology, FSM Teaching and Research Hospital, Istanbul, Turkey


2 Fatih Sultan Mehmet Egitim ve Arastirma Hastanesi, E-5 üzeri, Bostanci, Istanbul, Turkey


For all author emails, please log on.


Cases Journal 2008, 1:146 doi:10.1186/1757-1626-1-146


The electronic version of this article is the complete one and can be found online at: http://www.casesjournal.com/content/1/1/146


Received: 9 July 2008 Accepted: 9 September 2008 Published: 9 September 2008


© 2008 Gozke et al; licensee BioMed Central Ltd.


This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Abstract Introduction Creutzfeldt-Jacob Disease is the most frequently seen type of prion diseases. Its clinical findings consist of predominantly progressive dementia with a rapid onset, myoclonus, and also cerebellar, pyramidal, extrapyramidal and visual signs. Definitive diagnosis is established with histological examination of brain biopsy or autopsy materials. Occurrence of periodical spikes in EEG, observation of cortical signal alterations during diffusion weighted (DW) MRI studies, and detection of protein 14-3-3 in cerebrospinal fluid (CSF) substantiate the diagnosis.


Case presentation Seventy year-old male patient referred with complaints of weakness and involuntary movements in left arm, changes in behavior, and forgetfulness. He also developed akinetic mutism after nearly three months. In EEG periodic triphasic waves were seen. Despite the absence of any apparent pathological finding in T2 and FLAIR MRI, excluding signs of atrophy, on DW MRI hyperintense signal changes in cortical regions (cortical ribboning) were observed. Protein 14-3-3 in CSF was detected.


Conclusion Patients who have progressive dementia and associated atypical features should be investigated especially with DW MRI. Cortical ribboning is a very useful diagnostic sign for CJD.




SNIP...




Case presentation Three months before referral to our clinics, this 70 year-old patient experienced complaints such as difficulty in raising 3rd and 4th digits of his hands, insomnia, irritability, inability to find his way home. In cranial MRI bilateral cerebral cortical atrophy more prominent on the frontoparietal region was detected. The condition was evaluated as Alzheimer type dementia and cholinesterase inhibitors were initiated. To exclude the diagnosis of cervical radiculopathy and motor neuron disease, he underwent cervical MRI and EMG without detection of any specific finding. Two months after the onset of his complaints, visual hallucinations and tremor of the right hand were added. Cranial MRI was repeated without any detection of change. One month later neurologic examination revealed a mild degree of cognitive deficit, cerebellar signs in the right upper extremity and apraxia. The patient denied hospitalization for follow-up. Within ten days insomnia, irritability and agitation emerged, and he experienced delusions of being killed by their relatives, his speech became unintelligible and his gait instable. He was admitted to the hospital after a generalized tonic-clonic seizure. Neurological examination revealed drowsiness and disorientation. Facial asymmetry was absent, and extraocular movements were intact. Pupils were isochoric and at the midline with normal direct and indirect light reflexes. He was moving all his extremities in response to painful stimuli. Postural and action tremors and diffuse myoclonus emerging spontaneously and response to auditory or tactile stimuli were observed. Deep tendon reflexes were diminished, and planter reflexes were irrelevant bilaterally. Speech was extremely dysarthric and difficulty in swallowing was noted. Past medical history was unremarkable. Any abnormality besides lower TSH levels in laboratory tests could not be detected. From the 3rd day of his hospitalization akinetic mutism developed. EEG showed 4–5 cps teta waves in background activity and also slow triphasic waves with higher amplitude on frontal regions were detected. In differential diagnosis Hashimoto encephalitis was contemplated secondary to lower levels of TSH. Laboratory findings of the patient were interpreted as subclinical hyperthyrodism. Marked cerebral atrophy in frontoparietal regions and several ischemic-gliotic foci were seen on cranial MRI, T2 weighted and FLAIR imaging, while hyperintense areas (cortical ribboning) all over the cortex was noted in DW MRI (Figure 1). Any increase in signal intensity was not detected in putamen and caudate nucleus. In CSF examination protein, glucose and electrolyte levels were within normal limits and no cell seen. However 14-3-3 protein was positive. Patient diagnosed as sporadic CJD and died within 4 months after the onset of his complaints.




SNIP...




SEE FULL TEXT ;






TURKEY BSE GBR RISK ASSESSMENT IS BSE GBR 3 RISK LEVEL






Opinion of the Scientific Steering Committee on the GEOGRAPHICAL RISK OF BOVINE SPONGIFORM ENCEPHALOPATHY (GBR) in Turkey Adopted by the SSC on 27 June 2002


SNIP...


THE ANALYSIS EXTERNAL CHALLENGE The level of the external challenge that has to be met by the BSE/cattle system is estimated according to the guidance given by the SSC in its final opinion on the GBR of July 2000 (as updated in January 2002). Live cattle imports: In total the country imported over the period 1980-2001 more than 1.1 million live cattle from BSE-risk countries, of which 929 came from the UK. Most of these cattle were imported for immediate slaughter or fattening but overall these imports represent a very high external challenge. Broken down to 5-years periods the resulting external challenge resulting from live cattle imports was very low from 1980-1985, high from 1986 to 1990, very high from 1991-1995 and high thereafter. This assessment takes into account all aspects that allow assuming that certain imported cattle did not enter the domestic BSE/cattle system, i.e. were not rendered into feed, while approaching the end of the BSE-incubation period. MBM imports: In total the country imported over the period 1980 to 2001 more than 65.000 tons of MBM from BSE-risk countries but nothing from the UK. The claim that 90% of these imports were fishmeal or non-mammalian MBM was not substantiated. Together these imports are therefore assumed to represent a very high external challenge. Broken down to 5-years periods the resulting external challenge was high from 1980-1985, very high from 1986-1990, and moderate thereafter. This assessment takes into account all aspects that allow assuming that certain imported MBM did not represent an external challenge. STABILITY On the basis of the available information it was concluded that the country’s BSE/cattle system was very unstable from 1980 to 1995 and has been unstable since 1996/97. Feeding Until a feed ban was adopted in 1996/97, feeding MBM to ruminants was legally possible. Therefore feeding is assessed as "not OK" before 1997. Controls of the 1997-feed ban are in place since 1997 and feeding is regarded “reasonably OK” since 1996/97. Rendering Rendering was and is common practise in Turkey. SRM appear to be potentially included in the rendering but fallen stock is excluded. The process conditions seem to be generally appropriate but cannot be fully assessed as evidence for these and for controls is not supplied. Rendering is assessed as "reasonably OK" throughout the reference period. SRM-removal There is no SRM ban. While fallen stock is apparently not rendered it cannot be excluded that SRM entered/enters rendering. SRM removal is therefore assessed as “not OK” throughout the reference period. Scientific Steering Committee – Opinion on the GBR of TURKEY June 2002 - 4 - BSE surveillance Passive BSE surveillance existed since some time but BSE only became notifiable in 1997. Active surveillance has begun in June 2001 but this is not yet regarded to be sufficient to detect low levels of BSE-incidence. CONCLUSION ON THE CURRENT GBR The very unstable BSE/cattle system of Turkey was exposed to a high and very high external challenge since the early 80s. It is therefore likely that the BSE agent was introduced into the country and recycled and amplified. As the system is still regarded to be unstable it is concluded that it is likely but not confirmed that one or several domestic cattle are (pre-clinically or clinically) infected with the BSE-agent (GBR III). EXPECTED DEVELOPMENT OF THE GBR As long as the stability remains as low as it is, the probability of cattle to be (pre-clinically or clinically) infected with the BSE-agent will increase, also without any further external challenge.


SNIP...






NO Scrapie cases in Turkey ???


Distribution of risk groups in Turkish native sheep breeds for classical scrapie and atypical scrapie








all this sounds very familiar to me ;




Monday, May 19, 2008


SPORADIC CJD IN FARMERS, FARMERS WIVES, FROM FARMS WITH BSE HERD AND ABATTOIRS


‘The first farmer’ – August 1992


5.7 At the beginning of August 1992, Dr Will confidentially informed Dr Ailsa Wight (DH, senior medical officer with responsibility for TSEs), that a probable case of CJD had occurred in a 60-year-old farmer whose farm, in the Manchester area, had a history of BSE. Dr Wight passed on this information to Sir Kenneth Calman (CMO) on 13 August 1992, stating that the CJD patient was alive and had been visited by the CJDSU.188 Although unconfirmed, the diagnosis was considered likely to be CJD on clinical grounds. Dr Wight advised that: There is no direct evidence that the two events (BSE and CJD) are linked and Dr Will feels they are probably a coincidence. Despite the rarity of CJD, it was perhaps only a matter of time before this situation arose, given the large numbers of people employed in the agricultural and related industries, and the fact that BSE cases now total over 65,000.189


5.8 This ‘first case’ of CJD in a cattle farmer was discussed by SEAC190 at their 13th meeting on 15 October 1992.191 Dr Will informed the meeting that one of the farmer’s cows had confirmed BSE in 1989 and that the farmer had developed CJD two years later.192


5.9 Dr Will informed SEAC that he intended to publish a report of his study of this case in a scientific journal ‘which would probably draw the conclusion that there was no evidence that this was not a chance occurrence of normal disease’. Dr Will also reported that his studies at the CJDSU had failed to reveal a correlation between occupational backgrounds and CJD to date.193


5.10 On 22 October 1992, a minute from Mr Thomas Murray (SEAC DH Secretariat) informed the Secretary of State about the SEAC meeting and the fact that the farmer had now died.194 He noted that the diagnosis of CJD had been confirmed by pathology and that the CJDSU had also ruled out iatrogenic or familial CJD, as well as exposure to cattle brain. He commented that the SEAC meeting had come ‘to the view that all indications suggested that it was a typical sporadic case of CJD. However in view of the history it is hoped to carry out further laboratory studies to try to confirm this.’ 185


YB89/10.26/3.1 186 YB89/10.26/3.2 187 YB89/11.20/11.1 188 YB92/8.13/2.1–2.2 189 YB92/8.13/2.1–2.2 190


SEAC – Spongiform Encephalopathy Advisory Committee. This Committee was set up after advice from the Tyrrell Committee. Dr Will was a member of SEAC from its outset 191


YB92/10.15/2.1–2.8 192 YB92/10.15/2.4 193 YB92/10.15/2.4 194 YB/92/10.22/1.1–1.2


EMERGENCE OF VARIANT CJD 35 5.11


Dr Will published his report of the case, ‘Creutzfeldt-Jakob Disease in an Individual Occupationally Exposed to BSE’, as a letter in The Lancet on 6 March 1993.195 The letter concluded that ‘CJD in our case is most likely to have been a chance finding and a causal link with BSE is at most conjectural’. The letter noted that the only possible direct route of cross-contamination was that the farmer had drunk pooled milk from his herd which included that from the affected cow, but that epidemiological evidence had largely precluded milk as a route of transmission in spongiform encephalopathies.


5.12 This letter created much media interest over the following few days, and its contents were reported in The Times,196 Today,197 Daily Express,198 Daily Mail,199 and Daily Telegraph which also reported Mr Kevin Taylor (Assistant Chief Veterinary Officer, MAFF) stating ‘I don’t think that a link between this case and BSE is even conjectural’ and rejecting fears that the farmer might have contracted the illness from milk.200


5.13 On 10 March 1993, Mr Jimmy Young of BBC Radio 2, interviewed microbiologist Professor Richard Lacey, who commented that: The good news is that this farmer, I think, got it too soon. If BSE produces this disease in people it will take, perhaps, another 5 or 10 years. So I think this is a one-off coincidence and I don’t think this farmer got his disease, CJD, from BSE. But nevertheless the underlying worries remain and I think it’s reasonable that this issue should be discussed. 201


5.14 The Second Annual Report of the CJDSU, published in July 1993, concluded that: 202 This is most likely to have been a chance occurrence rather than indicating any causal link with BSE.


5.15 It further noted that: A farmer’s wife who was diagnosed in 1992 had worked on a small holding for over 20 years but there had not been a case of BSE in the herd (Wilesmith, Personal Communication).203


snip...


‘The second farmer’ – July 1993


5.16 In early July 1993, Dr Will informed DH of a ‘second’ case of CJD in a farmer with BSE in his herd. The diagnosis had been confirmed by brain biopsy.204


5.17 Dr Wight described the case in a minute sent on 12 July 1993 to the private secretaries to Baroness Cumberlege and Sir Kenneth Calman. The minute was copied to others in DH and to Mr Howard of MAFF. The 64-year-old dairy farmer from the West Country was thought to have had at least two BSE cases in his herd, which were diagnosed in 1992. He was also thought to have assisted in calving and to have drunk the milk from his herd. His clinical symptoms had begun in May 1993. She commented that the history did not suggest anything other than a sporadic case of CJD but that DH was taking expert advice on the case.205


5.18 On 19 July 1993, Mr Kevin Taylor (MAFF) minuted the private secretary to Mrs Gillian Shephard, the MAFF Minister, in a response to a request for more detailed briefing.206 He noted that neither Dr Will nor the CJDSU intended to publicise the case at that time unless it attracted media attention, as they intended to include the information in their Third Annual Report due in approximately one year, ie, July 1994.


5.19 The minute attached a briefing note for the Minister. This specifically mentioned the consideration of occupational exposure to BSE as discussed in the CJDSU’s Second Annual Report which concluded that: . . . current information does not suggest that occupation is linked to an increased risk of developing CJD and it includes occupations which might involve an increased exposure to the agent of BSE.207


5.20 On 20 July 1993, SEAC held a meeting to consider this ‘second case’.208 They decided that a connection between occupation and CJD was unlikely and no conclusions could be drawn from the available statistical information. A paper by Professor Smith was presented which concluded that ‘the observation of two cases in workers in dairy farms with BSE-infected herds is disquieting, but the evidence is insufficient at this stage to draw any definite conclusions’.209


5.21 On 12 August 1993, the Daily Mail and Today publicised the story of the ‘second case’ of CJD in a dairy farmer.210 Both named the farmer and reported a DH spokesman saying that the Government’s experts had considered the case and ‘agreed that there are no features that give cause for undue concern’. The spokesman had also commented that it was most unlikely that there was any direct link between BSE and CJD in the patient.


5.22 In September 1993, the case study of this ‘second farmer’ was published in The Lancet. This letter gave the farmer’s age as 54.211 204


YB93/7.12/1.1 205 YB93/7.12/1.1 206 YB93/7.19/1.1 207 IBD2 tab 6 p. 6 208 YB93/7.20/1.1 209 YB93/7.20/1.5 210 YB93/8.12/1.3–1.4 211 Davies, P.T., Jahfar, S., Ferguson, I.T. and Windl, O. (1993) Creutzfeldt-Jakob Disease in an Individual Occupationally Exposed to BSE, The Lancet, 342, 680


snip...


Her note had a separate heading for ‘Comparison with young onset cases in world literature’. Here she noted that Creutzfeldt’s first patient was 23 years old (reported in 1920), and that there were other cases of CJD in young people which predated the emergence of BSE. These were a 20-year-old female and a 16-year-old female in the US and a 19-year-old female in France.219


snip...


‘The third farmer’ – December 1994


5.33 A ‘third case’ associated with farming where cattle in the herd had contracted BSE concerned a farm worker from Cornwall who had died in early December 1994, aged 54. There had been two confirmed cases of BSE on the farm, in August 1991 and October 1992. Additionally, a cow sold off the farm in December 1987 had been diagnosed with BSE in September 1988.224


5.34 On 1 December 1994, the case was reported in the local newspaper, The Cornishman, while the patient was still in hospital.225


5.35 On 19 December 1994, Mr Charles Lister, DH, minuted the private secretary to Baroness Cumberlege with information about this possible ‘third case in farmers/ farm workers who have had BSE cases in their herds’.226 This minute enclosed the article from The Cornishman and was copied to DH officials and to Mr Eddy at 219


YB94/1.14/1.2 220 YB94/1.26/3.1 221 YB94/1.26/2.3; YB94/1.14/1.2 222 YB94/1.26/2.2 223


The report formed Annex 2 to the CJDSU’s Third Annual Report (IBD2 tab 8) 224


YB94/12.19/3.1 225 YB94/12.19/3.4 226 YB94/12.19/5.1


EMERGENCE OF VARIANT CJD 39 MAFF. He noted that diagnosis would not be confirmed until post mortem, but the Surveillance Unit thought it highly likely to be CJD.


5.36 On the same day, Mr Thomas Eddy, MAFF secretary to SEAC, passed the newspaper article and basic information about the case on to MAFF Ministers and officials.227


5.37 On 13 January 1995, SEAC held a special meeting to discuss the significance of this third case of CJD in a farmer in the first four years of surveillance.228 Dr Sheila Gore, an epidemiologist from the MRC Biostatistic Unit, was invited as an independent expert.


5.38 Detailed consideration was given to the case itself and the epidemiological implications. Dr Will commented that the post-mortem results were not yet available, but it was highly likely that the diagnosis of CJD would be confirmed. He stated that the man had no significant medical history and that he had worked as a farm labourer on the same dairy farm since 1955: The man was known to have assisted with calving but never with any operative procedure; he rarely drank unpasteurised milk and never from BSE-affected animals. It was not known if he had ever eaten cattle feed.229


5.39 As to the epidemiological significance of the case, the members recalled the advice given by Professor Smith after SEAC had considered the second case of CJD in a farmer: Professor Smith had advised that if four cases arose in the first 5 years of the surveillance scheme the possibility of an association which was not due to chance had to be given very serious consideration.230


5.40 Dr Gore commented that: If the adult incidence of sporadic CJD in the UK was taken as one case per million (the figure used by Professor Smith) and if the same incidence applied to workers on dairy farms with BSE-affected herds, then the probability of observing three or more definite CJD cases in such workers in England and Wales in 5 years was low: 4 in 1,000. The probability was higher if the calculation was made using the total number of dairy farm workers in England and Wales. However, this was considered to be less relevant as the only reported cases of CJD in dairy farm workers since 1990 had been in lifetime dairy workers all with BSE-affected herds.


snip...


5.63 On 29 September 1995, various newspapers reported the third case of CJD in a dairy farmer.255 Reference was made to a letter published in The Lancet (dated 30 September 1995) by Dr (now Professor) Smith (LSHTM).


5.64 The letter reported: The occurrence of CJD in another dairy farmer with a potential occupational exposure to BSE is clearly a matter of concern. Statistical analysis indicates that the probability of discovering three or more dairy farmers with CJD by chance since 1990 in England and Wales ranges from 0.09 to 0.0002, depending on the occupational denominator (individuals who work on farms to full-time workers on BSE-affected dairy farms).256


5.65 Statistics for CJD in European farmers were also reported in the 30 September 1995 edition of The Lancet.257 The paper concluded that ‘there is no differential increase in the risk of CJD to farmers in the UK through potential occupational contact with cases of BSE’. On the continent there was also a slightly higher proportion of cases of CJD arising in farmers.258 This indicated that in the UK, CJD in farmers had probably not arisen from transmission of BSE.259


The fourth farmer – September 1995


5.66 On 28 September 1995, Dr Wright minuted the private secretary to the CMO about a probable fourth case of CJD in a farmer. The 59-year-old beef farmer lived in North Wales and was alive when the case was reported to the CMO. The farm, which had a 70-strong suckler herd, had a confirmed case of BSE about four years previously in a 4½ to 5-year-old cow.260


5.67 The minute recorded the urgency of dealing with the issue as the case was in the public domain and BBC Wales were making a programme referring to the case.261 An urgent meeting of SEAC was called for the following week.


5.68 On 4 October 1995, SEAC held a special meeting to discuss this further suspected case of CJD in a cattle farmer.262 Professor Smith (LSHTM) and Dr Cousens (LSHTM) were in attendance to provide the Committee with expert epidemiological advice.263 5.69 Dr Will advised that although the Unit had initially clarified the case as probable CJD, he felt that it was more appropriate to look at it as a suspect case. Consideration was given by SEAC to European data that showed 12 cases of BSE in France, along with a progressive neurological disease in a farmer associated with 255


YB95/9.29/12.1; YB95/9.29/10.1; YB95/9.29/14.1 256


Smith, P.E., Zeidler, M., Ironside, J.W., Estibeiro, P. and Moss, T.H. (1995) Creutzfeldt-Jakob Disease in a Dairy Farmer, The Lancet, 346, 898 257 Delasnerie-Laupretre, N., Poser, S., Pocchiari, M., Wientjens, D.P. and Will, R. (1995) Creutzfeldt-Jakob Disease in Europe, The Lancet, 346, 898 258 T71 p. 115 259 T24 p. 95 260 YB95/9.28/3.1 261 YB95/9.28/3.1 262 YB95/10.4/1.1–1.8 263 YB95/10.04/1.1


EMERGENCE OF VARIANT CJD 45 one of those cases. (In the eventuality, this farmer was not diagnosed with CJD. At the beginning of January 2000, there had been no reported cases of CJD in farmers in France where BSE had been found in that farmer’s herd.)


5.70 Mr Wilesmith gave SEAC information about the farm associated with the possible UK fourth case of CJD under discussion. The farm had not been visited by MAFF. It had one case of BSE in a purchased animal which died in September 1991. From available information, the animals had not been fed on concentrates (although this had not been double-checked). It was thought, however, that the farm did have a big poultry battery unit, which may have meant that ruminant-derived feed was available on the farm.


5.71 Dr Cousens made a presentation of the epidemiology.264 He had calculated age specific mortality rates for sporadic CJD from 1990 to 1994 and applied these to data on farmers to calculate the expected number of sporadic CJD cases in farmers. The following conclusions were reached: i. there had been an alarming number of cases in farmers who had had contact with cattle with BSE. However, other occupational groups, expected to carry greater risk (eg, abattoir workers, veterinary surgeons), did not appear to be affected; ii. it was now difficult to explain the cases as a chance phenomenon. Yet the absolute risk still remained extremely low; iii. it was unclear whether the possible risk factor might be associated with cattle with BSE or the food given to them; and iv. as there was a problem with establishing a causal link, transmission studies would be extremely important.


5.72 At this meeting, Dr Wight invited members of SEAC to make a fairly clear statement on how they viewed the significance of a fourth case and to consider whether they were satisfied that nothing else needed to be done in terms of practical measures.265 In evidence to the Inquiry, Dr Wight said that trying to get a clear statement as to what would be a significant number of cases in farmers was bound to be difficult. She said, ‘I do not think that SEAC any more than anybody else had any idea how to make sense of this at this stage.’266 At the meeting, Dr Tyrrell’s response was that although numbers were higher than expected, they were still extremely small. It would be irrational to take specific measures at the moment. Members of SEAC agreed to draw up a statement which the Department of Health could issue in response to media inquiries.267 The text of the statement included the following:268 The Committee concluded that it was difficult to explain this simply as a chance phenomenon. There is a statistical excess in cattle farmers compared with the general population but the absolute risk, even for farmers, is extremely low at about 2 cases per million per year. There may be other explanations for such an association besides infection with BSE, and the Committee noted that there are no recorded cases in other occupational 264


YB95/10.4/1.2–1.4 265 YB95/10.4/4.5 266 T71 pp. 135–6 267 YB95/10.4/4.5 268 YB95/10.4/4.9


VARIANT CJD


46 groups such as veterinarians who might be expected to be similarly exposed. They also noted that the surveillance of CJD elsewhere in Europe has shown a similar incidence of CJD in farmers, including dairy farmers, in countries with no or very few cases of BSE. They therefore felt that it was important to undertake further epidemiological studies to detect any particular risk factors which might be involved, and reiterated their advice that the UK cases of CJD in cattle farmers and the strain of agent recovered from them should be studied in detail. The Committee have asked for further work to be done, but have not altered their advice to Government on the precautions necessary to protect either the public health, including farmers, and animal health.


5.73 Mr Eddy minuted the MAFF Minister and Parliamentary Secretaries advising them of the outcome of the SEAC meeting.269 He commented that SEAC had concluded that it would be worrying if the fourth case of CJD in a farmer from a BSE farm was confirmed. The chances of four CJD cases occurring randomly in farmers with BSE in their herds was . . . [since 1990] around 3/10,000. The Committee therefore concluded that it was difficult to explain the incidence as a chance phenomenon. This is a change to the Committee’s position; it had said that the most likely explanation of the three previous cases of CJD in dairy farm workers was that they were chance phenomena.270


5.74 Mr Eddy also stated that the SEAC did not recommend changes to any of the measures currently in place to protect human and animal health, including those of farmers and others handling cattle and BSE suspects.


5.75 On the same day, Mr Eddy prepared a second minute which was sent to Dr Matthews and Mr Keith Meldrum (CVO) amongst others about discussions during the SEAC meeting.271 Mr Eddy included a list of four ways in which the farmers might have been exposed to BSE that might have then led to their infection with CJD: i. cattle were excreting the agent in some form – no evidence for this; ii. meat and bone meal (MBM) in cattle feed – if so this would affect pig and poultry farmers equally (these feeds also contained MBM); iii. normal food – unclear why this discriminated in favour of farmers, although farmers could have been exposed to foods that other people might not have been routinely exposed to, such as unpasteurised milk; and iv. contact with animals – possibly animals killed on the farm.


snip..


5.93 Dr Will updated SEAC on CJD surveillance results at their 23rd meeting on 5 January 1996.292 He ‘reaffirmed that the incidence of CJD in dairy farmers in Europe showed an excess over the incidence for the population as a whole’. He confirmed that a 52-year-old abattoir worker from York was suspected of having CJD. The patient had worked mainly as a stockman in a mixed abattoir for 18 months in the late 1980s, and had occasionally pithed animals but had much less exposure than other abattoir workers. Dr Will believed that the patient was no more than a suspect at that stage.


5.94 The minutes of the meeting record that Professor Smith commented on this case: He [Professor Smith] felt that it was not possible to come to any conclusions on the basis of this case alone even if CJD is confirmed. Nevertheless, taking into consideration the affected farmers as well, and even though the abattoir worker was in an apparently relatively low risk category, the ‘box’ of ‘at 289 S61D Will para. 4 290 T138 p. 34 291 S61D Will para. 18 292


YB96/1.5/1.6–1.8; S61D Will paras 19–22


EMERGENCE OF VARIANT CJD 51 risk’ occupations was getting full compared to expectation on pure chance and could not be dismissed.293


snip...


Update on cases of CJD in farmers


5.152 During the period 1986–96, much attention and publicity was focussed on four cases of CJD in farmers (see above). Although those four cases were regarded as likely to be more than might be expected for the known population frequency of the disease, analysis of CJD in Europe showed the incidence of disease in farmers was similar to that in the UK.373 In addition, the clinical and pathological features of these cases were no different to those found in classical sporadic CJD.


5.153 It is understood that since 20 March 1996, at least two further cases of sporadic CJD in a relevant occupational group have been reported to the CJDSU, one in a farmer and another in an abattoir worker.374 Recent transmission studies in mice indicate that the causal agent in these cases has transmission characteristics (incubation period and neuropathology) which are distinct from both vCJD and BSE, and that the protein deposited in the brain in all of these cases has a glycosylation pattern distinct from the type 4 pattern observed in vCJD and BSE.


snip...


Is occupation a risk factor in vCJD?


5.192 One of the original proposals in the CJD surveillance project was to monitor occupational groups exposed to BSE-affected cattle and their products. Such groups include farmers, veterinarians, slaughtermen and butchers. This part of the project was given a low priority by the Tyrrell Committee and was not implemented. It was felt that rather than set up longitudinal study of a fixed number of individuals in each group, together with matched controls, it would be adequate to take an occupational history of each CJD case at the time of referral.


5.193 From 1990 to 1996, the CJDSU had referred to it four farmers affected with CJD who were known to have had cases of BSE on their farms. Assuming a total of 155,000 dairy farmers in the UK,384 the number of observed CJD cases is significantly higher than expected from population estimates. Counting only those farmers with affected cattle, the probability of observing four or more confirmed cases of CJD is estimated at less than one in 10,000.385 In addition, two farmers’ wives were known to have CJD from farms in which clinical BSE had not been reported (although preclinical cases of BSE on these farms might have been expected). 384 Gore, S. (1995) More than Happenstance: Creutzfeldt-Jakob Disease in Farmers and Young Adults, British Medical Journal, 311, 1416–8 385 Ibid.


EMERGENCE OF VARIANT CJD 79


5.194 The affected farmers were aged between 54 and 64 and had signs and symptoms typical of sporadic CJD. Two had EEG changes typical of the sporadic disease and all four had type 2 glycosylation patterns. Three farmers were homozygous for methionine at codon 129 and the fourth was a valine homozygote. None conformed to the phenotype characteristic of vCJD. The findings remained unexplained, although a European collaborative study showed a similar increased incidence in deaths due to CJD in farmers in several member states. It was noted that unexpected numbers of affected individuals occurred in other occupational groups, such as the clergy, but numbers in each occupation remained small.


5.195 Among occupational groups exposed to BSE, farmers remain unusual in having such an excess over the incidence of CJD for the population as a whole. No cases of CJD have been reported amount veterinarians exposed to BSE. Four people in the meat industry (butchers, abattoirs, rendering plants, etc) have been reported to have vCJD.386 The present evidence has been accepted by some as reassuring in that such occupations may not pose as serious a risk as might have been expected.




This was not simply another farmer but the third farmer......




suspect case of CJD in a farmer who has had a case of BSE in his beef suckler herd.






cover-up of 4th farm worker ???










CONFIRMATION OF CJD IN FOURTH FARMER




now story changes from;


SEAC concluded that, if the fourth case were confirmed, it would be worrying, especially as all four farmers with CJD would have had BSE cases on their farms.


to;


This is not unexpected...


was another farmer expected?




4th farmer, and 1st teenager






2. snip...


Over a 5 year period, which is the time period on which the advice from Professor Smith and Dr. Gore was based, and assuming a population of 120,000 dairy farm workers, and an annual incidence of 1 per million cases of CJD in the general population, a DAIRY FARM WORKER IS 5 TIMES MORE LIKELY THAN an individual in the general population to develop CJD. Using the actual current annual incidence of CJD in the UK of 0.7 per million, this figure becomes 7.5 TIMES.


3. You will recall that the advice provided by Professor Smith in 1993 and by Dr. Gore this month used the sub-population of dairy farm workers who had had a case of BSE on their farms - 63,000, which is approximately half the number of dairy farm workers - as a denominator. If the above sums are repeated using this denominator population, taking an annual incidence in the general population of 1 per million the observed rate in this sub-population is 10 TIMES, and taking an annual incidence of 0.7 per million, IT IS 15 TIMES (THE ''WORST CASE'' SCENARIO) than that in the general population...




CJD FARMERS WIFE 1989










20 year old died from sCJD in USA in 1980 and a 16 year old in 1981. A 19 year old died from sCJD in France in 1985. There is no evidence of an iatrogenic cause for those cases....






snip... see full text ;


Monday, May 19, 2008


SPORADIC CJD IN FARMERS, FARMERS WIVES, FROM FARMS WITH BSE HERD AND ABATTOIRS








-------- Original Message --------


Subject: Occupational risk factors for the sporadic form of Creutzfeldt-Jakob disease (FULL TEXT)


Date: Sat, 29 Nov 2003 13:09:20 –0600


From: "Terry S. Singeltary Sr."


{please note, scanned, copied, and corrected, could be errors..TSS)


La Medicina del Lavoro Med Lav 2003; 94,4:353-363


Occupational risk factors for the sporadic form of Creutzfeldt-Jakob disease


PL. Cocco, A. CAPERNA*, F. VINCI*


Dipardmento di Sanita Pubblica, Sezione di Medicina del Lavoro, Universita di Cagliari * Isdtuto di Medicina del Lavoro, Facolta di Medicina e Chirurgia A. Gemelli, Universita Cattolica del Sacro Cuore, Roma




KEYWORDS




Creutzfeldt-Jakob disease; epidemiology; occupational health




SUMMARY




Some case reports among European farmers and a few case-control studies suggested the hypothesis of an increased risk of the sporadic form of CJD (sCJD) associated with livestock farming or work as a butcher. Also, the discovery of the possibility of transmission of the disease via blood or by contact following corneal or dura madre transplant suggested that health occupations might also run higher sCJD risks. However, a meta-analysis of three case-control studies and a multicentre European study did not find any positive association between sCJD and health-related jobs or occupational contact with livestock, such as cattle and sheep, or animal products. To explore possible occupational risk factors for Creutzfeldt-Jakob disease (CJD), we used a publicly available US database including about 6 million deaths in 24 states during 1984-95. Cases were 636 deaths (300 men and 336 women) with CJD (ICD-9 code 046.1) as the underlying cause of death. Controls were 3,180 deaths randomly selected from among those who died from all other diseases except those affecting the central nervous system. CJD cases represented a wide variety of occupations (159) and industries (147). Among occupations and industries, for which previous reports suggested potential exposure to a transmissible spongiform encephalopathy (TSE) agent, the OR for CJD was significantly increased among butchers (OR=6.8, 95% C.I. 1.5, 30.1, based on 4 cases and 3 controls), and persons working in offices of physicians (OR=4.6, 95% C.I. 1.2, 17.6 based on 5 cases and 4 controls). Nine other occupations and seven other industries, for which no previous suggestion existed in the literature, also showed significant associations. Overall, our results suggest that occupational exposures are not an important source of sCJD infection. However, as the excess among butchers and some workers in health occupations was consistent with previous reports, more indepth research is warranted to address the hypothesis.




RiASSUNTO




«Fattori di rischio professlonale per la forma sporadica della malattia di CreutzfeIdt-Jakob». L'epidemia delta cosiddetta "nuova variante" della malattia di Creutzfeldt-Jakob (CJD) in Gran Bretagna, e la sua dimostrata associazione con l'epidemia di encefalopatia spongiforme bovina (BSE) in quello stesso Paese, hanno ridestato l'in-




Pervenuto il 28.11.2002 - Accettato il 15.1.2003



Corrispondenza: Diparrimento di Sanita Pubblica, Sezione di Medicina del Lavoro, Universita di Cagliari, via San Giorgio 12,


09124 Cagliari - Tel. 070-60285278 - Fax 070654350 - E-mail: coccop@pacs.unica.it




Comunicazione orale alia XXV Riunione Annuale dell'Associazlone Italiana di Epidemioloeia, Venezia 4 Ottobre 2001




354


COCCO ET AL




teresse nei confronti di tutte leforme di questa rara malattia e del suo possibile rapporto con alcune esposizioni in amblto lavorativo. La descrizione di alcuni casi di CJD in contadini europeifece ipotizzare che attivita quail l'all-evamento di bovini o l'abbattimento degli stessi in mattatoi potessero comportare un aumento del rischio di CJD. Inoltre, la possibility di una trasmissione per via ematica o per contatto con materiali biologici, successivamente ai trapianfi di dtira madre o di cornea, fece sospettare che anche le professioni sanitane potessero comportare un aumento del rischio di CJD. Tuttavia, una meta-analisi di tre studi caso-controllo non dimostro una associazione tra forma sporadica di CJD ed attivita sanitarie o contatto con bovini ed ovini, ed uno studio multicentrico Europeo non trovb akuna associazione con I'esposizione professionale ad animali o pelli, mentre itrischio risultava elevato perfrequents esposizlone a cuoio ed esposizione a fertilizzanti contenenti zoccoli e coma. La dispombilita di un data-base pubblicamente accessible, contenente i dati di circa 6 milioni di certificati di morte in 24 Stati degli Stati Uniti nel periodo 1984-95, ha consentito I'esplorazione dei rischi occupazionali di CJD in questo Paese. Sono stati individual in tutto 636 casi (300 uomini e 336 donne) di decessi per CJD (ICD-9 046.1). Come controlli sono stati selezionati 3180 soggetti deceduti per altre patologie, ad esclusione di quelle a carico del sistema nervoso centrale, accoppiati in rapporto di 5:1 ai casi per area geografica'di residenza, sesso, razza edeta. Tra le occupaziom sospettate a priori di un'associazione, i macellai mostravano un OR di 6,8 (I.F. 95% 1,5, 30,1, basato su 4 casi e 3 controlli), ma un risultato simile veniva osservato anche in altre nove occupazioni non sospettate a priori di un'associazione. Il rischio non risultava elevato per Ie attivita agricole nel complesso, o nelle Industrie alimentan, mentre un OR di 4,6 (I.F. 95% 1,2, 17,6, basato su 5 casi e 4 controlli) era associate al lavoro in ambulaton medici, ma non in ospedali o altri servizi sanitari. Altre sette attivita industriali, non sospettate a priori di un'associazione, mostravano un significative aumento del rischio di CJD. La dispersione dei casi di CJD in una grande varieta di occupazioni induce a ritenere che le esposizioni professionali contribuiscano scarsamente all'eziologia della forma sporadica di CJD. D'altro canto, i risultati positivi potrebbero essere genera ti dal caso data la molteplicita di con-fronti effettuati. Tuttavia, appare opportuna la pianificazione di indagini multicentriche piu approfondite che testino l'ipotesi del ruolo di esposizioni professionali nell 'attivita di abbattimento degli animali, insieme ad altri possibili fattori di rischio, nell'eziologia di questa rara malattia.




INTRODUCTION




The UK epidemics of the new variant form of Creutzfeldt-Jakob disease (nvCJD), and its link with bovine spongiform encephalopathy (BSE) (46, 47) has raised interest in searching for etiolog- ical clues for the more commonly seen, classic forms of CJD. Classic CJD is a neurological disor- der, classified in the group of transmissible spongi- form encephalopathies (TSEs), that has been esti- mated to affect approximately 1x10-6 persons per year worldwide. It is invariably fatal, with a mean illness duration of 5 months (47), and a median age at death of 68 years (20). Some TSEs in humans have been shown to be associated with mutations in the prion protein (PrP) gene (PRNP) on chro- mosome 20 (32), and a few are classified as familial CJD. In patients affected by the non-familial spo- radic form of classic CJD (about 85% of CJD cas- es), a significantly increased prevalence of homozy-gosity for methionine or valine at PrP codon 129 has been reported (25, 28, 37, 40). Based on the scarce geographical variation in the occurrence of sporadic CJD over long time periods, it has been proposed that there is no environmental source of infection (16, 31) and that the vast majority of cas- es rather result from de novo spontaneous genera- tion of a transmissible agent consisting of an ab- normal form of a host-encoded glycoprotein (31). This transmissible agent was given the name of "prion" in 1982 (30). However, a 5-fold inter-re- gional variation in the crude CJD mortality rate occurred within Italy in 1993-99 (8). Also, the pro- portion of polymorphism at codon 129 among sCJD cases is more similar to that observed among persons with iatrogemc CJD, than to that in the general population, which suggested that simple stochastic events would not fully explain SCJD (33). Also, sCJD cases are tipically elderly, with cortical symptoms, and abnormal PrP, but not amyloid, deposits in the synapses, On the other hand, nvCJD typically affects young people; it is not associated with codon 129 polymorphism and it does present amyloid plaques in the brain (47).




CJD AND OCCUPATION




355





A substantial body of evidence supports the hy- pothesis of blood transmission of the sCJD agent in various animal species (41), depending on the tissue level of PrP infectivity, the species barrier, and the route of administration (33). However, the risk of CJD transmission by transfusion remains theoretical, since no confirmed cases have ever been causally attributed to the receipt of a blood transfusion, nor has any case developed in recipi- ents of clotting factor concentrates, or pooled plas- ma derivatives, to which a donor, who subsequently developed CJD, had contributed (15, 27, 41). Also, no known cases of CJD were attributable to the reuse of percutaneous transluminal coronary angio- plasty (PTCA) equipment contaminated by blood (15). While the potential exists for blood transmis- sion of the disease, thus far human epidemiological evidence suggests that such an occurrence would be rare, as only a small fraction of the general popula- tion carrying codon 129 and codon 200 polymor- phisms might be susceptible to infection, and most transfusions might not contain infective doses suf- ficient to cause the disease (33). On the other hand, the hypothesis of a transmissible agent, pos- sibly with blood, is supported by numerous clinical reports of iatrogenic CJD consistently identifying surgical procedures as a risk factor. Although such a possibility was ruled out in an early study among French cases occurring in 1968-77 (4), CJD cases have been described after dura madre or corneal transplants from infected donors (14, 21, 24, 26, 27, 29), neurosurgery of stereotactical encephalog- raphy with contaminated instruments (3, 49), use of GH hormonal extracts from cadavers (2), and three epidemiological studies showed a higher sCJD risk following general surgery (9, 22, 43). However, while Australian authors interpreted the evidence as an indication of the possibility of dis- ease transmission (9), German authors suggested stress as the relevant risk factor (22). Due to the exceptional resistance of the infecting agent to common sterilising agents, autoclave and sodium hypochloride or hydroxide treatment, or formic acid treatment of infected materials and instru- ments has been suggested to prevent occupational and/or iatrogenic transmission of the disease (34, 36), while formadehyde was not effective in pre- venting transmission (33).




If blood transmission were important, occupa- tional contact with animal blood, organs, and other animal products would be a plausible co-factor in sCJD etiology. In the pre-nvCJD-epidemic era, the hypothesis of CJD as a zoonotic disease was raised (23). As early as 1986, such a hypothesis was again raised in a small French study (11). Occupational contact with animals such as deer, monkeys, and squirrels was associated with a non-significant 9- fold increase in risk, while the excess risk of similar degree associated with non occupational contact with deer or rabbits was statistically significant. Exposure to animal organs was also significantly associated with CJD (OR=20.9; p<0.005) (11). Following the nvCJD epidemics in the UK, clinical reports of sCJD cases among livestock farmers and butchers have been repeatedly published (17, 35, 44, 48), further suggesting that - if the link were to be confirmed in analytical studies — transmission via the blood or skin contact through skin lesions with infected materials and/or instruments would be important (19). Analytical studies have been less numerous, and they are reported in table 1. A meta-analysis of three case-control studies on sCJD published at that time concluded that a non significant association existed with livestock farm- ing and with health related occupations (45). The study of 662 sCJD deaths in 1970-96 in the Unit- ed Kingdom found a significant excess risk among livestock farmers (6 observed deaths versus 2.4 ex- pected), although the interpretation was limited to the absence of any link with the nvCJD epidemics (10). All the observed cases were livestock farmers, four of whom (0.6 expected) occurred in farms where BSE cases had been reported. No cases were observed among veterinarians (0.03 expected), or butchers. (0.15 expected). A matched case-control study of 206 sCJD cases and controls did not iden- tify any association with a priori suspected occupa- tions (38). However, 21 cases (10%) e 14 controls (7%) occurred in subjects with occupational contact with animal products (p=0.17). The authors did not explore this finding in detail. We conducted a crude calculation based on the published data, and we found instead an Odds Ratio of 1.6 (95% confi- dence interval 1.18,2.15).




356




COCCO ET AL




Table 1 - Studies of sCJD and occupation


Author


Type of study Health Raising Butchers,


occupations cattle/sheep abattoir workers


Wientjens et al, 1996


Cousens et al, 1997


UK Nat CJD Surv Unit, 1997


Van Duijn et al, 1998


Aylin et al, 1999


UK Nat CJD Surv Unit, 2001**


Meta-analysis Cohort


Case-control


Case-control


Trend in proportional mortality


Case-control


snip...not available...tss


* contact with animal products; ** combining nvCJD and sCJD cases






A European case-control study was conducted by interviewing next-of-kins of 405 CJD cases and 405 hospital controls, excluding patients suffering from dementia (42) .The authors reported a signifi- cant excess risk associated with the use of fertilizers containing substances derived from hoofs and horns, and with contact with skin and fur not as garments. Among individual occupations, only butchers showed a non-significant increase in the Odds Ratio. A proportional mortality analysis of deaths from dementia in England and Wales dur- ing 1979-96 did not find a consistently increasing temporal trend in occupations suspected a priori of being at risk, such as farmers, butchers and abattoir workers, and veterinarians (1). Another prelimi- nary combined case-control analysis of 102 nvCJD cases and 197 sCJD cases, compared to 195 con- trols, found no excess risk among health related oc- cupations, butchers and abattoir workers, and other occupations involving contact with animal products (39). Eight out of 114 identified cases in Slovakia had health related occupations (25).The authors excluded a link between occupational factors and CJD risk, although no formal analysis was con- ducted in this regard, nor any information was pro- vided on which were the occupations of the other 106 cases.




It is possible that, in the studies conducted thus far, the small number of subjects in the occupations at risk limited the exposure assessment to ever hav- ing held a job considered a priori at risk, indepen- dently of the period in the lifetime, duration, type of animals, and actual job content. The methods section of these papers do not explain whether complete work histories were included in the ques- tionnaire, or whether only one or more main occu- pational titles or the last were collected. A further problem in these studies is that information for cases always relied on next-of-kin reporting, whilst the same study subjects provided the information in about half the hospital controls and in all popu- lation controls.




Overall, the results of the studies conducted thus far stress the fundamental requirement of having experts in occupational epidemiology, agricultural work technology and veterinarian hygiene par- ticipating in planning and analyzing occupational data.




To examine the possible association of CJD with occupational risk factors, we accessed a large pub- licly available database, including death certificate from 24 US states in 1984-95, to analyze the occu- pations of the 636 deaths due to CJD therein re- ported in comparison to 3,180 controls deceased from other selected causes of death, in a country thus far not affected by the nvCJD epidemics.




METHODS




The 24 US states death certificates database we used consists of several million coded death certfi- cates from 24 US states, covering the years 1984- 95. The 24 states are: Colorado, Georgia, Idaho (from 1988), Indiana (from 1986), Kansas, Ken- tucky, Missouri (in 1984-86), Maine, Nebraska (in




CJD AND OCCUPATION


357




1984-85), Nevada, New Hampshire, New Jersey (from 1988), New Mexico (from 1986), North Carolina (from 1987), Ohio (from 1985), Okla- homa, Rhode Island, South Carolina, Tennessee (in 1985-88), Utah (from 1985), Vermont, West Virginia (from 1988), Washington (from 1989), and Wisconsin. In addition to standardized coding procedures, information on usual occupation and kind of business or industry, reported in the death certificate for each decedent, was included in the database provided to the National Center for Health Statistics (NCHS) (7). The information on occupation and industry was coded according to the 1980 US Bureau of the Census classification (6). The underlying cause of death was coded ac- cording to the International Classification of Dis- eases - 9th revision. No further details, such as du- ration of employment or concurrent diseases, are available from this database. Among subjects 25 years of age or more at death, 636 cases of CJD (ICD-9 code 046.1) were identified. Table 2 shows the case distribution by age, and gender. Only 22 subjects were indicated as non-whites in the data base. As we did not see any reason why a gross def- inition of genetic background, such as the demo- graphic concept of "race", should affect sCJD risk, we included all subjects in the analysis. Eligible controls were subjects who died from all other dis- eases, except mental disorders (ICD-9 codes 290.0-319.9), diseases of the central nervous sys- tem (ICD-9 codes 320.0-349.9), cerebrovascular diseases (ICD-9 codes 430.0-438.9), unspecified atherosclerosis (ICD-9 code 440.9), and ill defined conditions and symptoms involving the central nervous system (ICD-9 codes 780.0-781.9). We randomly selected five controls per each case with- in the set of controls with the same geographic re- gion, race, gender, 5-year age group, and year of death as the index case. The Odds Ratio (OR) as- sociated with a given occupation or industry cate- gory was expressed relative to an unexposed refer- ence group including all other occupation or indus- try categories.




Table 2 - Deaths from Creutzfeldt-Jakob disease in 24 US states in 1984-95 by age, and gender




Age group Men Women


25-39 3 4


40-49 11 16


50-59 47 46


60-69 126 121


70-79 92 117


80 + 21 32


All ages 300 336






Odds Ratios (ORs) and their 95% confidence intervals (95% C.I.) were derived from the respec- tive log odds obtained with logistic regression modeling, using the GMBO feature of the Epi- cure® software. ORs were calculated for selected demographic variables. We first calculated OR for those occupations and industries for which litera- ture reports suggested a potential association with CJD. For occupations, these prior hypotheses were livestock farmers, veterinarians, butchers and other food-related occupations, pathologists and other health professionals. For industries, those consid- ered as prior hypotheses were livestock tanning, slaughterhouses and meat processing plants, hospi- tals and other health facilities. Secondly, we calcu- lated OR for all occupations and industries for which there were three or more exposed cases. Co- variates in the logistic regression model for occupa- tion and industry were age (5-year age categories), marital status (never-married versus ever-married), and socioeconomic status (SES) (five categories). The SES indicator was obtained by categorizing the Greens Standardized Scores for Specific Occu- pations (13,18), as follows:




- low SES (score 21-39);


- medium-low SES (score 40-49);


- medium SES (score 50-59); 4. medium-high SES (score 60-64);


- high SES (score >65). Introducing gender as a covariate in the logistic regression model did not change the risk estimates.


RESULTS


In the present study population, female cases are more numerous than male, and more than 94 per- cent of the cases died at age 50 or older (table 2). Subjects who died from CJD were less likely to have never been married and to have lived in the South, and slightly more likely to have resided in metropol- itan areas (not shown in the tables). The OR for CJD increased with higher SES (test for trend, p<0.001). This association persisted within strata of latitude, geographic region, race (although numbers were very small among African Americans), gender, age, and marital status (not shown in the tables).




COCCO ET AL






Overall, 159 occupation and 147 industry cate- gories were represented among CJD cases, with 52 of the occupation and 54 of the industry categories composed of at least three cases. A statistically sig- nificant association with CJD was observed for 10/52 occupation categories (19%) and 8/54 indus- try categories (15%), including disparate activities such as financial managers, mechanical engineers, teachers, military personnel, and persons working in manufacture of toys, amusement, and sporting goods, telephone utility companies, beauty shops, and financial services (table 3). These associations varied very little after limiting the analysis to sub- jects aged 40 years or older.




Among food handling occupations, a prior hy- pothesis in this study, a statistically significant asso- ciation was observed for butchers (OR=6.8, 95% C.I. 1.5, 30.1, based on 4 cases and 3 controls). The OR was non-significantly elevated for miscella- neous food preparation occupations (Census code 444: OR=3.2, 95% C.I. 0.9, 10.7, based on 4 cases and 9 controls), a heterogeneous category which in- corporates food preparation occupations other than those with specific codes (such as cooks, waiters, or bartenders). When we combined all food prepara- tion occupations, no association was observed (OR=1.1; 95% C.I. 0.5,2.3, based on 9 cases and 41 controls), suggesting that the observed excesses were restricted to butchers and miscellaneous food preparation occupations. No cases or controls were coded as non-farm animal caretakers. One case and no controls were classified as a hunter or trapper. When examined by industry grouping (table 3) the ORs were non significantly elevated in the meat products industry (OR=3.8, 95% C.I. 0.8, 17.3, based on 3 cases and 4 controls).




CJD was not associated with agricultural work. The occupation of non horticultural farmer showed a non significant 20% increase in risk. Among in- dustries, a similar result was observed for crop pro- duction (OR=1.2; 95% C.I. 0.6, 2.4, based on 12 cases and 73 controls), and livestock farming (OR=1.2, 95% C.I. 0.3, 4.2, based on 3 cases and 17 controls).




Health-related occupations and industries were also a prior hypothesis in this study. The excess ob- served among physicians was not statistically sig- nificant (OR=4.6, 95% C.I. 0.7, 29.0, based on 3 cases and 2 controls). No excess was observed for nurses (occupational codes 095 and 207 combined:




OR=0.8, 95% C.I. 0.4, 1.5; based on 12 cases and 55 controls), or for all health related occupations combined (OR=0.8; 95% C.I. 0.5, 1.5, based on 13 cases and 72 controls). No pathologists were re- ported among cases. No veterinarians were report- ed among cases versus one among controls.




Among health-related industries, a significant association was observed for persons working in offices of physicians (OR=4.6, 95% C.I. 1.2, 17.6, based on 5 cases and 4 controls), but not for those working in hospitals (OR=1.0, 95% C.I. 0.6, 1.7, based on 22 cases and 95 controls), or health ser- vices not elsewhere classified (OR=1.1, 95% C.I. 0.3, 3.8, based on 3 cases and 13 controls).




For the occupations and industries shown in table 3, being a prior hypothesis of this study did not increase the likelihood of a significant association with CJD (1/6 or 17% significant findings among prior hypotheses versus 9/46 or 20% among the other occupations, and 1/7 or 14% among prior hypotheses compared with 7/47 or 15% among the other in- dustries).




DISCUSSION




In this death certificate based case-control study, we observed a statistically significant association of CJD with work as a butcher and with employment in the office of a physician, occupation and indus- try categories for which previous literature reports suggested potential exposure to a TSE agent. However, other occupations and industries for which the same hypothesis was raised, such as work on a livestock farm, were unassociated with CJD. The positive associations with the occupation of butcher and employment in physician's offices cannot be conclusively interpreted because of the small numbers and lack of information on the type and extent of exposure to potentially infectious material. Also, other generally smaller studies of CJD in Europe have not found specific associa- tions with livestock farming or other specific occu- pations, including health care workers (1,42).




CJD AND OCCUPATION




In our study, significant associations were found for CJD with 19 percent of the occupations and 15 percent of the industries composed of at least three cases, and these proportions did not vary according to being a prior hypothesis in this study or not. A proportion of positive findings (about 5%) would be expected to occur by chance. Relative differences in ascertainment may also have contributed to pos- itive findings for some high SES employment cate- gories, such as financial managers, engineers, teachers, drafting occupations, or work in insurance firms and financial industries. In this data set, risk for other neurological diseases, including amyothrophic lateral sclerosis, multiple sclerosis, and Parkinson's disease, also showed this pattern (data not shown), suggesting a generalized diag- nostic bias related to SES in diseases requiring a more sophisticated diagnostic evaluation. The pos- sible under-ascertainment of CJD deaths in the lower SES categories may also explain some of the deficit in CJD mortality previously reported among African Americans compared to whites in the USA (20). Therefore, as described in the methods sec- tion, we adjusted by SES all risk estimates. The in- crease in CJD risk for butchers and employees in physicians offices persisted in the unadjusted analysis or when the analysis was restricted to the SES category they belonged.




An important limitation in our study is that it was based on the one occupation and industry combination on the death certificate of study sub- jects, and no further details, such as duration of employment, were available. This should be con- sidered when interpreting our findings. One strength of our study is the large number of CJD deaths available for analysis (636 cases), as we uti- lized the largest database possible to evaluate the relationship of CJD with occupational risk factors. Still, the numbers for specific occupations and in- dustries are quite small, and chance could account for the increases in risk observed in our study.




Disease misclassification was likely to be a mi- nor problem in this study, as death certificates have been shown to be a reasonably specific source for ascertaining CJD cases (5, 12), and control subject;




were selected after excluding deaths linked to diag- nostic codes conceivably including misdiagnosed CJD cases. However, as it is not possible to distin- guish familial from non-familial CJD cases within a data base of coded death certificates, we cannot assess whether and to what extent individual find- ings may have been biased by poor diagnostic in- formation.




While chance could account for the associations we observed, their consistency with other pub- lished clinical and epidemiological reports indicate that further in-depth studies are warranted to eval- uate the findings among butchers and employees in physician's offices before concluding for a CJD ex- cess in these jobs. The rarity of the sCJD has pre- vented substantial progress in the knowledge of its etiological factors. The international multicentre approach, and a detailed occupational exposure as- sessment performed by experts, would be crucial in successfully identifying candidate risk factors...




CJD AND OCCUPATION




Table 3 - Odds Ratio for Creutzfeldt-Jakob disease associated with selected industries and occupations (at least 3 exposed cases)




Census/Code...............Cases/Controls..........OR(95%C.I.)




007 - Financial managers 6/5 4.2 (1.2-14.8)


019 - Managers and administrators, n.e.c. 36/151 0.9 (0.5-1.3)


023 - Accountants and auditors 6/24 0.9 (0.4-2.4)


056 - Industrial engineers 3/3 3.0 (0.6-15.6)


057 - Mechanical engineers 7/4 6.0(1.6-22.2)


084 - Physicians 3/2 4.6 (0.7-29.0)


095 + 207 - Registered nurses & licensed practical nurses 12/55 0.8 (0.4-1.5)


156 - Teachers, elementary school 16/63 1.0(0.5-1.8)


157 - Teachers, secondary schools 3/4 2.8 (0.6-12.8)


159 - Teachers, n.e.c. 5/6 3.5 (1.0-11.8)


176 - Clergy 3/14 1.1 (0.3-3.9)


185 - Designers 3/8 1.4 (0.4-5.5)


217 - Drafting occupations 3/4 3.8 (0.8-17.2)


243 - Supervisors and proprietors, sales occupations 22/97 1.1 (0.7-1.8)


253 - Insurance sales occupations 5/11 1.8 (0.8-5.3)


254 - Real estate occupations 3/9 1.3 (0.3-4.8)


259 - Sales representatives, mining, manufacturing, wholesale 7/16 1.7 (0.7-4.2)


263 - Sales workers, motor vehicles and boats 4/9 2.2 (0.7-7.0)


274 - Sales workers, other commodities 8/59 0.7 (0.3-1.4)


313 - Secretaries 14/73 1.0 (0.5-1.7)


337 - Bookkeepers, accounting, and auditing clerks 8/30 1.3 (0.6-2.9)


379 - General office clerks 10/30 1.7 (0.8-3.4)


407 - Private household cleaners and servants 9/39 1.7 (0.8-3.8)


417 - Firefighting occupations 3/7 2.1 (0.5-8.1)


435 - Walters and waitresses 4/22 1.1 (0.4-3.4)


436 - Cooks, except short order 5/30 1.1 (0.4-2.8)


444 - Miscellaneous food preparation occupations 4/9 3.2 (0.9-10.7)


447 - Nursing aides, orderlies, and attendants 3/39 0.5 (0.1-1.6)


449 - Maids and housemen 3/7 2.8 (0.7-11.0)


453 - Janitors and cleaners 5/50 0.7(0.3-1.7)


458 - Hairdressers and cosmetologists 6/8 3.7 (1.3-10.7)


473 - Farmers, except horticultural 14/87 1.2 (0.6-2.3)


518 - Industrial machinery repairers 3/3 5.2 (1.0-26.1)


529 - Telephone installers and repairers 3/2 7.2 (1.2-43.4)


558 - Supervisors, n.e.c. 3/17 0.9 (0.2-2.9)


563 - Bnckmasons and stonemasons 3/4 5.0(1.1-22.7)


567 - Carpenters 4/41 0.6 (0.2-1.7)


575 - Electricians 4/15 1.3 (0.4-4.0)


633 - Supervisors, production occupations 10/40 1.2 (0.6-2.5)


637 - Machinists 6/22 1.3 (0.5-3.3)


653 - Sheet metal workers 3/4 3.8 (0.8-17.2)


686 - Butchers 4/3 6.8 (1.5-30.1)


744 - Textile sewing machine operators 5/28 1.2 (0.4-3.1)


757 - Separating, filtering &, clarifying machine operators 3/2 7.2 (1.2-43.4)


779 - Machine operators, not specified 10/25 2.0 (0.9-4.2)


783 - Welders and cutters 3/20 0.9 (0.3-3.2)


785 - Assemblers 9/31 1.9 (0.9-4.2)


804 - Truck drivers, heavy 7/62 0.7(0.3-1.5)


844 - Operating engineers 3/7 2.1 (0.5-8.1)


877 - Stock handlers and baggers 3/8 2.0 (0.5-7.6)


889 - Laborers except construction 16/93 1.3 (0.7-2.5)


905 - Military 10/23 2.2 (1.0-4.6)




Table 3 - continued


Census/Code Cases/Controls OR (95% C.I.)




Industries


010 - Agricultural production, crops 12/73 1.2 (0.6-2.4)


O11 - Agricultural production, livestock 3/17 1.2 (0.3-4.2)


060 - Construction 26/179 0.8 (0.5-1.2)


100 - Meat products 3/4 3.8 (0.8-17.3)


142 - Yarn, thread and fabric mills 10/49 1.2 (0.6-2.4)


151 - Apparel and accessories, except knit 3/23 0.8 (0.2-2.6)


160 - Pulp, paper, and paperboard mills 4/12 1.7 (0.5-5.3)


172 - Printing and publishing, except newspapers 4/20 0.9 (0.3-2.8)


181 - Drugs manufacturing 3/5 3.0 (0.7-12.7)


192 - Industrial and miscellaneous chemicals 3/14 1.1 (0.3-3.9)


200 - Petroleum refining 3/11 1.2 (0.3-4.6)


270 - Blast furnaces, steelworks, rolling, and finishing 9/27 1.7 (0.8-3.7)


280 - Other primary metal industries 3/6 2.6 (0.6-10.3)


320 - Metal working machinery manufacturing 3/4 3.6 (0.8-16.4)


331 - Machinery except electrical, n.e.c. 5/20 1.1 (0.4-3.0)


342 - Electrical machinery, equipment and supplies 4/24 0.8 (0.3-2.4)


351 - Motor vehicles and motor vehicle equipment 13/43 1.7(0.9-3.1)


352 - Aircrafts and parts 6/16 1.8 (0.7-4.5)


371 - Scientific and controlling instruments 3/7 1.9 (0.5-7.5)


390 - Toys amusement, and sporting goods 3/1 18.3 (1.9-177)


392 - Not specified manufacturing industries 11/57 1.1 (0.6-2.1)


400 - Railroads 4/31 0.6 (0.2-1.8)


410 - Trucking service 9/51 1.0 (0.5-2.0)


441 - Telephone (wire and radio) 10/17 2.7 (1.2-5.9)


552 - Wholesale trade of petroleum products 3/4 3.8 (0.8-17.1)


601 - Grocery stores 4/33 0.6 (0.2-1.8)


612 - Motor vehicle dealers 9/25 1.8 (0.8-3.9)


620 - Auto and home supply stores 3/5 2.9 (0.7-12.1)


621 - Gasoline service stations 6/12 2.8 (1.0-7.4)


630 - Apparel and accessories stores, except shoe 4/17 1.1 (0.4-3.3)


641 - Eating and drinking places 13/70 1.0(0.5-1.8)


682 - Miscellaneous retail stores 3/13 1.1 (0.3-3.9)


691 - Not specified retail trade 3/25 0.6 (0.2-1.9)


700 - Banking 6/14 1.7 (0.7-4.6)


710 - Security, commodity brokerage, & invest, companies 3/4 3.5 (0.8-15.8)


711 - Insurance 17/29 2.6 (1.4-4.7)


712 - Real estate 9/30 1.3 (0.6-2.7)


742 - Business services, n.e.c. 3/18 0.8 (0.2-2.6)


751 - Automotive repair shops 4/18 1.3 (0.4-3.9)


760 - Miscellaneous repair services 3/15 1.1 (0.3-3.7)


761 - Private households 9/46 1.4 (0.7-3.1)


772 - Beauty shops 6/10 3.0(1.1-8.3)




812 - Offices of physicians 5/4 4.6 (1.2-17.6)


831 - Hospitals 22/95 1.0(0.6-1.7)


832 - Nursing and personal care facilities 3/21 0.8 (0.2-2.6)


840 - Health services, n.e.c. 3/13 1.1 (0.3-3.8)


842 - Elementary and secondary schools 34/128 1.2(0.8-1,8)


880 - Religious organizations 3/23 0.7 (0.2-2.3)


890 - Accounting, auditing, and bookkeeping services 4/9 1.9 (0.6-6.1)


901 - General government, not elsewhere classified 6/37 0.8 (0.3-1.8)


910 - Justice, public order, and safety 8/34 1.1 (0.5-2.5)


921 - Public finance, taxation, and monetary policy 4/3 5.5 (1.2-24.8)


931 - Administration and economic programs 3/10 1.4(0.4-5.0)


942 - Armed Forces 10/22 2.3 (1.1-4.9)


Note: N.e.c. = not elsewhere classified


REFERENCES


1.AYLIN P, BUNTING J, DE STAVOLA B, COLEMAN MP: Mortality from dementia in occupations at risk of exposure to bovine spongiform encephalopathy: analysis of death registrations. Br Med J 1999; 318: 1044-1045


2. BILLETTE DE VILLEMEUR T, DESLYS JP, PRADEL A, et al: Creutzfeldt-Jakob disease from contaminated growth hormone extracts in France. Neurology 1996; 47: 690- 695


3. BROWN P: Environmental causes of human spongiform encephalopathy. In Baker H, Ridley RM (eds): Methods in Molecular Medicine: firion diseases. Totawa (NJ): Hu- mana Press Inc, 1996:139-154


4. BROWN P, CATHALA F, GAJDUSEK DC: Creutzfeldt- Jakob disease in France: III. Epidemiological study of 170 patients dving during the decade 1968-1977. Ann Neurol 1979;6:438-446


5. BRUTON CJ, BRUTON RK, GENTLEMAN SM, ROBERTS GW: Diagnosis and incidence of prion (Creutzfeldt- Jakob) disease: a retrospective archival survey with im- plications for future research. Neurodegeneration 1995; 4: 357-368


6. BUREAU OF THE CENSUS: Alphabetical Index of Indus- tries and Occupations. Washington (DC): US Depart- ment of Commerce, PHC80R3,1982


7. BURNETT CA, MAURER J, DOSEMECI M: Mortality by occupation, industry, and cause of death. 24 reporting states, 1984-1988. Cincinnati (OH): US Department of Health and Human Services, Centers for Disease Con- trol, National Institute for Occupation Safety and Health, 1997 (DHHS - NIOSH publication No 97- 114)


8.CAPERNA A, TANZILLI P, CANNAS M, VINCI P:


Creutzfeldt-Jakob disease e rischio occupazionale. Folia Medica 2000; 71:177-185


9. COLLINS S, LAW MG, FLETCHER A, et al: Surgical treatment and risk of sporadic Creutzfeldt-Jakob dis- ease: a case-control study. Lancet 1999; 353: 693-697


10. COUSENS SN, ZEIDLER M, ESMONDE TF, et al: Spo- radic Creutzfeldt-Jakob disease in the United King- dom: analysis of epidemiological surveillance data for 1970-96. BMJ 1997; 315:389-395


11. DAVANIPOUR Z, ALTER M, SOBEL E, et al: Transmissi- ble virus dementia: evaluation of a zoonotic hypothesis. Neuroepidemiology 1986; 5: 194-206


12. DAVANIPOUR Z, SMOAK C, BOHR T, et al: Death cer- tificates: an efficient source for ascertainment of Creutzfeldt-Jakob disease. Neuroepidemiology 1995; 14:1-6


13. DOSEMECI M, HAYES RB, VETTER R, et al: Occupa- tional physical activity, socioeconomic status, and risks of 15 cancer sites in Turkey. Cancer Causes Control 1993;4: 313-321


14. ESMONDE T, LUECK CJD, SYMON L, et al: Creutzfeldt- Jakob disease and lyophilised dura mater grafts: report of two cases. J Neurol Neurosurg Psychiat 1994; 56: 999-1000


15. FAGIH B, EISENBERG MJ: Reuse of angioplasty catheters and risk of Creutzfeldt-Jakob disease. Am HeartJ 1999; 137:1173-1178


16. GAJDUSEK DC: Infectious amyloids: subacute spongi- form encephalopathies as transmissible cerebral amyloi- doses. In Fields BN, Knipe D, Howley PM, et al (eds): Virology, 3rd ed. Philadelphia (PA): Lippincott-Raven, 1996:2851-2900


17. GORE SM: More than happenstance: Creutzfeldt- Jakob disease in farmers and young adults. Br Med J 1995; J.U:1416-1418


18. GREEN L: Manual for scoring socioeconomic status for research on health behavior. Public Health Rep 1970; 85: 815-827


19. HOFMAN A, WIENTJENS PWM: Epidemiological evi- dence concerning possible causal link. Br Med J 1995; 311:1418-1419


20. HOLMAN RC, KHAN AS, BELAY ED, SCHONBERGER LB: Creutzfeldt-Jakob disease in the United States, 1979-1994: Using national mortality data to assess the possible occurrence of variant cases. Emerg Infect Dis 1996:2:333-337


21.LANG CJ, HECKMANN JG, NEUNDORFER B: Creutzfeldt-Jakob disease via dural and corneal trans- plants. J Neurol Sd 1998; 160:128-139


22. LASK.E C, GEFELLER 0, PFAHLBERG A, et al: The ef- fect of stress on the onset and progression of Creutzfeldt-Jakob disease: results of a German pilot case-control study. EurJ Epidemiol 1999; 15: 631-635


23. MASTERS CL, HARRIS JO, GAJDUSEK DC, et al: Creutzfeldt-Jakob disease: patterns of worldwide occur- rence and the significance of familial and sporadic clus- tering. Ann Neurol 1979; 5:177-188


24. MASULLO C, POCCHIARI M, NERI G, et al. A retro- spective study of Creutzfeldt-Jakob disease in Italy (1972-1986). EurJ Epidemiol 1988; 4: 482-487


25. MITROVA E, BELAY G: Creutzfeldt-Jakob disease in health professionals in Slovakia. Eur J Epidemiol 2000; 16: 353-355


26. NAKAMURA Y, ASO E, YANAGAWA H: Relative risk of Creutzfeldt-Jakob disease with cadaveric dura trans- plantation in Japan. Neurology 1999; 53:218-220


27. NAKAMURA Y, OKI I, TANIHARA S, et al: A case-con- trol study of Creutzfeldt-Jakob disease in Japan: trans- plantation of cadaveric dura mater was a risk factor. J Epidemiol 2000; 10: 399-402


28. PLAITAKIS A, VISKADOURAKI AK, TZAGOURNISSAKIS M, et al: Increased incidence of sporadic Creutzfeldt- Jakob disease on the island of Crete associated with a high rate of PRNP 129-methionine homozygosity in the local population. Ann Neurol 2001; 50:227-233


29. PRICHARD J, THADANI V, KA.LE R, et al: Rapidly pro- gressive dementia in a patient who received a cadaveric dura mater graft. MMWR Morb Mortal Wkly Rep 1987; 36:49-50


30. PRUSINER SB: Novel proteinaceous infectious particles cause scrapie. Science 1996; 216:136-144


31. PRUSINER SB: Prions. In Fields BN, Knipe DM, How- ley PM, et al (eds): Virology, 3-' ed. Philadelphia (PA): Lippincott-Raven, 1996: 2901-2950


32. PRUSINER SB, HSIAO KH: Human prion diseases. Ann Neurol 1994; 35: 385-395


33-RICKETTS MN, CASHMAN NR, STRATTON EE, ElSAADANY S: Is Creutzfeldt-Jakob disease transmitted in blood? Emerg Infect Dis 1997; 3:155-163


34. RUTALA WA, WEBER DJ: Creutzfeldt-Jakob disease:


CJD AND OCCUPATION


363


recommendations for disinfection and sterilization. Clin Infect Dis 2001; 32:1348-1356


35. SMITH PEM, ZEIDLER M, IRONSIDE JW, et al: Creutzfeldt-Jakob disease in a dairy farmer. Lancet 1995;346: 898


36.TAYLOR DM: The effect of formic acid on BSE and scrapie infecrivity in fixed and unfixed brain tissue. Vet Microbiol 1997; 58:167-174


37. THE EUROCJD GROUP: Genetic epidemiology of Creutzfeldt-Jakob disease in Europe. Rev Neurol 2001; 157: 633-637


38. THE NATIONAL CJD SURVEILLANCE UNIT: Creutzfeldt-Jakob Disease surveillance in the UK. Sixth Annual Report 1997. London (UK): Department of In- fectious and Tropical Disease, London School of Hy- giene and tropical Medicine, 1997


39. THE NATIONAL CJD SURVEILLANCE UNIT: Creutzfeldt-Jakob Disease surveillance in the U.K. Tenth Annual Report 2001. London (UK): Department of In- fectious and Tropical Disease, London School of Hy- giene and tropical Medicine, 2001


40. TYLER KL: Risk of human exposure to bovine spongi- form encephalopathy. Br MedJ 1995; 311:1420-1421


41. VAMVAKAS EC: Risk of transmission of Creutzfeldt- Jakob disease by transfusion of blood, plasma, and plas- ma derivatives. J Clin Apheresis 1999; 14:135-143


42. VAN DUIJN CM, DELASNERIE-LAUPETRE N, MASULLO C, et al: Case-control study of risk factors of Creutzfeldt-Jakob disease in Europe during 1993-95. European Union (EU) Collaborative Study Group of Creutzfeldt-Jakob disease (CJD). Lancet 1998; 351: 1081-1085


43. WARD HJ, EVERINGTON D, CROES EA, et al: Sporadic Creutzfeldt-Jakob disease and surgery; a case-control study using community controls. Neurology 2002; 59: 543-548


44. WEIS J, KRETZSCHMAR HA, WINDL 0, et al: Fatal spongiform encephalopathy in a patient who had han- dled animal feed. Lancet 1996; 348:1240


45. WIENTJENS DPWM, DAVANIPOUR Z, HOFMAN A, et al: Risk factors for Creutzfeldt-Jakob disease: a reanaly- sis of case-control studies. Neurology 1996; 46: 1287- 1291


46. WILL RG, IRONSIDE JW, ZEIDLER M, et al: A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 1996;347: 921-925


47. WORLD HEALTH ORGANIZATION CONSULTATION GROUP: Public health issues and clinical and neurologi- cal characteristics of the new variant of Creutzfeldt- Jakob disease and other human and animal transmissi- ble spongiform encephalopathies: memorandum from two WHO meetings. Bull World Health Organ 1996; 74: 453-463


48. YOUNG GR, FLETCHER NA, ZEIDLER M, et al: Creutzfeldt-Jakob disease in a beef farmer. Lancet 1996; 348: 610-611


49. ZERR I, BRANDEL JP, MASULLO C, et al: European sur- veillance on Creutzfeldt-Jakob disease: a case-control study for medical risk factors. J Clin Epidemiol 2000; 53: 747-754




=============




UPDATE 2011




Monday, January 17, 2011


Aerosols Transmit Prions to Immunocompetent and Immunodeficient Mice






Thursday, December 22, 2011


Risk of Prion Disease Transmission through Bovine-Derived Bone Substitutes: A Systematic Review Clin Implant Dent Relat Res. 2011 Dec 15. doi: 10.1111/j.1708-8208.2011.00407.x. [Epub ahead of print]






Saturday, December 3, 2011


Candidate Cell Substrates, Vaccine Production, and Transmissible Spongiform Encephalopathies


Volume 17, Number 12—December 2011






Friday, December 23, 2011


Oral Transmission of L-type Bovine Spongiform Encephalopathy in Primate Model


Volume 18, Number 1—January 2012 Dispatch






Saturday, December 3, 2011


Isolation of Prion with BSE Properties from Farmed Goat Volume 17, Number 12—December 2011






Monday, July 18, 2011



Impact of Being Placed at Risk of Creutzfeldt-Jakob Disease: A Qualitative Study of Blood Donors to Variant CJD Cases and Patients Potentially Surgically Exposed to CJD







Tuesday, March 29, 2011


TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY EXPOSURE SPREADING VIA HOSPITALS AND SURGICAL PROCEDURES AROUND THE GLOBE






Wednesday, June 29, 2011


TSEAC Meeting August 1, 2011 donor deferral ...






Monday, October 10, 2011 EFSA Journal 2011 The European Response to BSE: A Success Story


snip...


EFSA and the European Centre for Disease Prevention and Control (ECDC) recently delivered a scientific opinion on any possible epidemiological or molecular association between TSEs in animals and humans (EFSA Panel on Biological Hazards (BIOHAZ) and ECDC, 2011). This opinion confirmed Classical BSE prions as the only TSE agents demonstrated to be zoonotic so far but the possibility that a small proportion of human cases so far classified as "sporadic" CJD are of zoonotic origin could not be excluded. Moreover, transmission experiments to non-human primates suggest that some TSE agents in addition to Classical BSE prions in cattle (namely L-type Atypical BSE, Classical BSE in sheep, transmissible mink encephalopathy (TME) and chronic wasting disease (CWD) agents) might have zoonotic potential.


snip...









see follow-up here about North America BSE Mad Cow TSE prion risk factors, and the ever emerging strains of Transmissible Spongiform Encephalopathy in many species here in the USA, including humans ;






Wednesday, June 15, 2011


Galveston, Texas - Isle port moves through thousands of heifers headed to Russia, none from Texas, Alabama, or Washington, due to BSE risk factor






Wednesday, March 31, 2010


Atypical BSE in Cattle


To date the OIE/WAHO assumes that the human and animal health standards set out in the BSE chapter for classical BSE (C-Type) applies to all forms of BSE which include the H-type and L-type atypical forms. This assumption is scientifically not completely justified and accumulating evidence suggests that this may in fact not be the case. Molecular characterization and the spatial distribution pattern of histopathologic lesions and immunohistochemistry (IHC) signals are used to identify and characterize atypical BSE. Both the L-type and H-type atypical cases display significant differences in the conformation and spatial accumulation of the disease associated prion protein (PrPSc) in brains of afflicted cattle. Transmission studies in bovine transgenic and wild type mouse models support that the atypical BSE types might be unique strains because they have different incubation times and lesion profiles when compared to C-type BSE. When L-type BSE was inoculated into ovine transgenic mice and Syrian hamster the resulting molecular fingerprint had changed, either in the first or a subsequent passage, from L-type into C-type BSE. In addition, non-human primates are specifically susceptible for atypical BSE as demonstrated by an approximately 50% shortened incubation time for L-type BSE as compared to C-type. Considering the current scientific information available, it cannot be assumed that these different BSE types pose the same human health risks as C-type BSE or that these risks are mitigated by the same protective measures.


This study will contribute to a correct definition of specified risk material (SRM) in atypical BSE. The incumbent of this position will develop new and transfer existing, ultra-sensitive methods for the detection of atypical BSE in tissue of experimentally infected cattle.






Thursday, August 12, 2010


Seven main threats for the future linked to prions


First threat


The TSE road map defining the evolution of European policy for protection against prion diseases is based on a certain numbers of hypotheses some of which may turn out to be erroneous. In particular, a form of BSE (called atypical Bovine Spongiform Encephalopathy), recently identified by systematic testing in aged cattle without clinical signs, may be the origin of classical BSE and thus potentially constitute a reservoir, which may be impossible to eradicate if a sporadic origin is confirmed.


***Also, a link is suspected between atypical BSE and some apparently sporadic cases of Creutzfeldt-Jakob disease in humans. These atypical BSE cases constitute an unforeseen first threat that could sharply modify the European approach to prion diseases.


Second threat


snip...





Saturday, November 19, 2011


Novel Prion Protein in BSE-affected Cattle, Switzerland






Price of PRION TSE aka MAD COW POKER GOES UP $$$


Saturday, December 3, 2011


Isolation of Prion with BSE Properties from Farmed Goat Volume 17, Number 12—December 2011






Saturday, June 25, 2011


Transmissibility of BSE-L and Cattle-Adapted TME Prion Strain to Cynomolgus Macaque


"BSE-L in North America may have existed for decades"






Over the next 8-10 weeks, approximately 40% of all the adult mink on the farm died from TME.


snip...


The rancher was a ''dead stock'' feeder using mostly (>95%) downer or dead dairy cattle...






2010-2011


When L-type BSE was inoculated into ovine transgenic mice and Syrian hamster the resulting molecular fingerprint had changed, either in the first or a subsequent passage, from L-type into C-type BSE. In addition, non-human primates are specifically susceptible for atypical BSE as demonstrated by an approximately 50% shortened incubation time for L-type BSE as compared to C-type. Considering the current scientific information available, it cannot be assumed that these different BSE types pose the same human health risks as C-type BSE or that these risks are mitigated by the same protective measures. This study will contribute to a correct definition of specified risk material (SRM) in atypical BSE. The incumbent of this position will develop new and transfer existing, ultra-sensitive methods for the detection of atypical BSE in tissue of experimentally infected cattle.






Discussion: The C, L and H type BSE cases in Canada exhibit molecular characteristics similar to those described for classical and atypical BSE cases from Europe and Japan. This supports the theory that the importation of BSE contaminated feedstuff is the source of C-type BSE in Canada.


*** It also suggests a similar cause or source for atypical BSE in these countries.






Saturday, July 23, 2011


CATTLE HEADS WITH TONSILS, BEEF TONGUES, SPINAL CORD, SPECIFIED RISK MATERIALS (SRM's) AND PRIONS, AKA MAD COW DISEASE






Saturday, November 6, 2010


TAFS1 Position Paper on Position Paper on Relaxation of the Feed Ban in the EU


Berne, 2010 TAFS INTERNATIONAL FORUM FOR TRANSMISSIBLE ANIMAL DISEASES AND FOOD SAFETY a non-profit Swiss Foundation






Archive Number 20101206.4364 Published Date 06-DEC-2010 Subject PRO/AH/EDR>


Prion disease update 2010 (11) PRION DISEASE UPDATE 2010 (11)






October 2009 O.11.3 Infectivity in skeletal muscle of BASE-infected cattle


Silvia Suardi1, Chiara Vimercati1, Fabio Moda1, Ruggerone Margherita1, Ilaria Campagnani1, Guerino Lombardi2, Daniela Gelmetti2, Martin H. Groschup3, Anne Buschmann3, Cristina Casalone4, Maria Caramelli4, Salvatore Monaco5, Gianluigi Zanusso5, Fabrizio Tagliavini1 1Carlo Besta" Neurological Institute,Italy; 2IZS Brescia, Italy; 33FLI Insel Riems, D, Germany; 4CEA-IZS Torino, Italy; 5University of Verona, Italy


Background: BASE is an atypical form of bovine spongiform encephalopathy caused by a prion strain distinct from that of BSE. Upon experimental transmission to cattle, BASE induces a previously unrecognized disease phenotype marked by mental dullness and progressive atrophy of hind limb musculature. Whether affected muscles contain infectivity is unknown. This is a critical issue since the BASE strain is readily transmissible to a variety of hosts including primates, suggesting that humans may be susceptible.


Objectives: To investigate the distribution of infectivity in peripheral tissues of cattle experimentally infected with BASE. Methods: Groups of Tg mice expressing bovine PrP (Tgbov XV, n= 7-15/group) were inoculated both i.c. and i.p. with 10% homogenates of a variety of tissues including brain, spleen, cervical lymph node, kidney and skeletal muscle (m. longissimus dorsi) from cattle intracerebrally infected with BASE. No PrPres was detectable in the peripheral tissues used for inoculation either by immunohistochemistry or Western blot.


Results: Mice inoculated with BASE-brain homogenates showed clinical signs of disease with incubation and survival times of 175±15 and 207±12 days. Five out of seven mice challenged with skeletal muscle developed a similar neurological disorder, with incubation and survival times of 380±11 and 410±12 days. At present (700 days after inoculation) mice challenged with the other peripheral tissues are still healthy. The neuropathological phenotype and PrPres type of the affected mice inoculated either with brain or muscle were indistinguishable and matched those of Tgbov XV mice infected with natural BASE.


Discussion: Our data indicate that the skeletal muscle of cattle experimentally infected with BASE contains significant amount of infectivity, at variance with BSE-affected cattle, raising the issue of intraspecies transmission and the potential risk for humans. Experiments are in progress to assess the presence of infectivity in skeletal muscles of natural BASE.






2011 Monday, September 26, 2011


L-BSE BASE prion and atypical sporadic CJD






SEE RISE OF SPORADIC CJD YEAR TO YEAR ;






Saturday, June 18, 2011


Self-propagation and transmission of misfolded mutant SOD1 Prion or Prion-like phenomenon?








Thursday, August 4, 2011




Terry Singeltary Sr. on the Creutzfeldt-Jakob Disease Public Health Crisis, Date aired: 27 Jun 2011


SEE VIDEO ;
























FULL TEXT WITH SOURCE REFERENCES ;












TSS

Thursday, December 29, 2011

Aerosols An underestimated vehicle for transmission of prion diseases?

Aerosols

 An underestimated vehicle for transmission of prion diseases?


 Lothar Stitz1,* and Adriano Aguzzi2


 1Institute of Immunology; Friedrich-Loeffler-Institut; Tübingen, Germany; 2Institute of Neuropathology; University of Zürich; Zürich, Switzerland


 We and others have recently reported that prions can be transmitted to mice via aerosols. These reports spurred a lively public discussion on the possible public-health threats represented by prion-containing aerosols. Here we offer our view on the context in which these findings should be placed. On the one hand, the fact that nebulized prions can transmit disease cannot be taken to signify that prions are airborne under natural circumstances. On the other hand, it appears important to underscore the fact that aerosols can originate very easily in a broad variety of experimental and natural environmental conditions. Aerosols are a virtually unavoidable consequence of the handling of fluids; complete prevention of the generation of aerosols is very difficult. While prions have never been found to be transmissible via aerosols under natural conditions, it appears prudent to strive to minimize exposure to potentially prion-infected aerosols whenever the latter may arise—for example in scientific and diagnostic laboratories handling brain matter, cerebrospinal fluids and other potentially contaminated materials, as well as abattoirs. Equally important is that prion biosafety training be focused on the control of, and protection from, prion-infected aerosols.


 Prions, the causative agents of transmissible spongiform encephalopathies, can be undoubtedly propagated from one individual organism to another. The specific routes of prion transmission have been subjected to intensive studies over the past two decades. Incidental and iatrogenic transmission has occurred through the intracerebral route in the case of Dura mater implants1 and the parenteral route in the case of contaminated pituitary hormones.2 In addition, the Bovine Spongiform Encephalopathy (BSE) disaster has provided grim evidence that prion can be transmitted enterally as well. Experimental transmission of prions has been routinely achieved via intraperitoneal and intravenous injection3,4 but also through more exotic routes such as intralingual,5 intranerval6 and conjunctival inoculation7 and via the nasal cavity.8


 In all prion disease paradigms studied so far the propagation, accumulation and dissemination of the prion protein has been mostly shown to depend on a functional immune system.9-12 This dependence of prion pathogenesis on the lymphoid compartment, however, is only true for peripheral routes of infection—whereas direct inoculation into the brain does not require any components of the adaptive or innate immune system.


 B cells in secondary lymphoid organs have been shown to be of importance for the neuroinvasion of the prion protein; in contrast, B lymphocytes in the blood do not appear to play a crucial role.13-15


 A special role in prion pathogenesis can be assigned to follicular dendritic cells (FDC). The generation, maturation and function of FDC are dependent on cytokines and chemokines predominantly synthesized and secreted by B lymphocytes. Consistently with this role of B cells in prion pathogenesis, B-cell deficient mice show a significantly impaired prion replication due to severely impaired maturation of FDCs.16 Other soluble and membrane-bound immune mediators such as lymphotoxin heterotrimers and TNFa17,18 as well as components of the complement system,19,20 play an important role in prion pathogenesis.


 While prions mostly reside in tissues, prion infectivity has also been detected in a variety of body fluids including cerebrospinal fluid,21 blood,22 saliva,23 milk24 and urine.25 Although shedding of prions may occur constitutively from these secretions and excretions, many of the latter phenomena are enhanced by chronic inflammatory processes such as granulomas26 and follicular infiltrates,27 which trigger the maturation of lymphotoxin-dependent, prion-replicating cells.26 The presence of prions in fluids begs the question whether nebulization, and subsequent inhalation, of such fluids may trigger prion infections.


 Aerosols are finely dispersed particles originating from solid material or liquid using air or other gases as carriers. Natural examples of aerosols include dust (e.g., volcano ashes), smoke, haze and sprays (e.g., sneezing or sea water sprays from breaking waves). Aerosols might be formally categorized as primary or secondary, with primary aerosols being generated in mechanical or thermal processes e.g., by whirling up, impact on surfaces, or burning, whereas secondary aerosols are generated during chemical reactions or by using condensation nuclei.


 Primary aerosols play an important role in microbiology since they can act as efficacious vehicles for pollen, spores, algae, fungi, bacteria and viruses. Of medical importance are also dandruff, fragments of fur, hairs or skin and mites, which can all function as allergens and trigger allergic asthma.


 Moreover, aerosols are excellent vehicles for the transportation of drugs into the respiratory tract. The size of the individual droplets is crucial in specifying the target organs of aerosol. Particle sized 3–10 μm are generally deposited in the nasal cavity and in the throat, whereas smaller particles (e.g., 1 μm) tend to deposit within the lower airways. In rodents pulmonary deposition can reach 10%.28,29 In humans, particles of 5 μm may reach the lung if inhaled orally, but deposition in the alveolar compartment after inhaling via the nose is highly unlikely.28,29 For the reasons discussed above, we have become interested in exploring the transmission potential of aerosol-borne prions.


 Indeed, we found that mouse scrapie can be efficiently transmitted via aerosols.30 In addition to results obtained by exposure to aerosols, we found that mice developed prion infections when inoculated intranasally.


 Interestingly, this route of transmission was entirely independent on immune cells as shown by challenging various transgenic mouse strains lacking defined functions of the immune system.


 Well-known examples of transmission of pathogens via aerosols are infections by respiratory viruses (e.g., influenza viruses, adenoviruses, rhinoviruses, coronaviruses) and bacterial diseases (e.g., legionellosis, pneumonic plague by Yersinia pestis, Q-fever by Coxiella burnettii, anthrax) and fungal diseases (particularly aspergillosis and candidosis). In stark contrast, aerosols have historically never been regarded as potential vectors for prion diseases— although very little data existed in favor or against this possibility. This attitude goes along with the implicit “conventional wisdom” that prions are not airborne diseases. However, the concept of “airborne disease” in all the bacterial, fungal and viral examples quoted above, encompasses three distinct phases: (1) release of the infectious agent into aerosols by an infected donor, (2) uptake by a healthy recipient and (3) establishment of disease. It is self-evident that little or no natural transmission between individuals will be observed if any one of these three steps is inefficient. The epidemiological evidence from human prion diseases seems to indicate, albeit indirectly, that step 1 does not occur in CJD patients—inter alia because there is a dearth of evidence of proximity clustering of sCJD.31 In the case of CWD the situation may be different since saliva and droppings, which might plausibly give rise to powerful aerosols under a variety of conditions, were found to harbor infectivity. Finally, milk from sheep affected by mastitis can carry scrapie infectivity and—again—could conceivably give rise to aerosols. Since both CWD and sheep scrapie can efficiently spread horizontally within animal collectives, it is extremely appealing to speculate whether aerosols may play a role in said transmission.


 In natural scrapie in sheep horizontal transmission of prion diseases has been long thought to arise from placental contamination. However, in mice suffering from nephritis prion infectivity is shed with the urine.25 Furthermore, sheep having a mastitis can transmit infectious prions with milk.32


 In Chronic Wasting disease (CWD) of deer several careful studies have been performed that, together with our present finding, depose in favor of airborne transmission in this naturally occurring disease. Indeed, CWD prions can be transmitted experimentally via aerosol and the nasal route to transgenic cervidized mice.33 Although no anecdotal or epidemiological evidence has come forward that airborne transmission may be important for the spread of CWD, several lines of thought suggest that this possibility is not implausible. In deer, prions have been detected in urine, saliva, feces and blood of diseased animals. Moreover, it was claimed that pathological prion protein could be recovered from the environmental water in an endemic area.34 Since all fluids can act as sources for the generation of aerosols, any of the body fluids mentioned above may represent the point of origin for airborne transmission of CWD prions.


 In this context, also the presence of infectious prions in blood of patients should be mentioned which was demonstrated by the transmission of vCJD by blood transfusions.35,36 The growing body of evidence that prion transmission can be airborne—at least under certain conditions—dictates that the release of potentially contaminated aerosols should be avoided under all circumstances. In this context it is mandatory that reliable precautions be defined and followed in scientific and diagnostic laboratories. In particular, it is self-evident that safety cabinets should be used while processing brain and nerve tissue (or any other potentially contaminated tissue) of man and animals suspected with prion disease. Our experience shows that this necessity is generally very well-understood by prion scientists.


 A further stone of contention relates to the biosafety level of the laboratory environment. Because prions were hitherto considered not be airborne, so far no specific regulations have been implemented. As a consequence, prion laboratories have been mostly required to adhere to the category “BSL3**.” While it is understood that the airborne transmission of prions has thus far only been observed under extreme conditions, we feel that it is in order to critically reassess biosafety regulations in the light of the recent discoveries. In particular, one might consider implementing more stringent measures towards protecting workers within diagnostic and scientific laboratories from aerosols.


 The situation in slaughterhouses and plants handling potentially contaminated offal may be even more problematic. Although regulations in slaughterhouses dictate the use of protecting glasses and masks or, alternatively, visors the use of personal protecting equipment should be rigorously controlled. In addition, high-pressure cleaning devices produce massive aerosols and should be strictly avoided in areas of slaughterhouses where prion-containing material may be processed. Regulations concerning cleaning of heads from slaughtered animals do pay attention to aerosol avoidance, e.g., by allowing only water hoses without pressure.


 A case in point is the severe neurological syndrome arising in swine abattoir workers.37 Here, an immune-mediated polyradiculoneuropathy was reported to be related to a process using high-pressure fluids to remove the brains of swine.37 During this process, high amounts of swine brain tissue became aerosolized and were inhaled and/or gained access to the respiratory tract mucosa of abattoir workers, resulting in immunization with myelin constituents akin to experimental autoimmune encephalitis (EAE). Although significant physiological differences exist concerning breathing, where humans are regarded as mouth breathers and mice as nose breathers, many people indeed show nose breathing under no or only moderate body burden. Therefore, results obtained in mouse experiments might also be extrapolated to a considerable extent to the situation in man.


 In this context it is of importance to stress again that aerosols might be generated under various conditions and represent a normal entity of the environment in a variety of daily life situations.


 In our studies of airborne transmission of prion protein in mice30 we took advantage of the fact that mice breathe exclusively through their nostrils38,39 and therefore could be exposed in groups to aerosolized brain suspensions. Using this system, it was possible to vary both time of exposure as well as concentration of the prion load in the aerosol. We were surprised to discover that exposure times as short as 1 min were sufficient to achieve high attack rates. By extending the time of exposure it became obvious that incubation times were shortened. A possible alternative route of infection via the cornea or the conjunctiva was extremely unlikely, since newborn mice, whose eyelids were still closed, could also be infected. These findings show that the aerogenic transmission of prions is very efficient.


 But how do prions spread from the airways to the brain? Peripheral replication of prions in the lymphoid system—a characteristic of most other peripheral routes of transmission—appeared to be dispensable. Instead, the results argue for a direct pathway of brain invasion. One anatomical peculiarity of the nasal cavity is the “area cribriformis” of the olfactory epithelium. Here the olfactory bulb sprouts axons of olfactory receptor neurons passing through the cribriform plate of the ethmoidal bone to reach the olfactory mucosa where olfactory cilia extend representing non-myelinated nerve endings. Thus, open nerve endings are located in the nasal cavity through which aerosolized infectious prions might get access to the brain. In this context it is noteworthy that pathological prion protein was found in the olfactory cilia and basal cells of the olfactory mucosa of sCJD patients, as well as in the olfactory bulb and olfactory tract.40,41 However, it was hitherto never clearly documented that olfactory receptor neurons represent an entry site for infectious prions; this might also be due to the sensitivity threshold of detection assays.


 In conclusion, aerosols can infect mice with a surprisingly high efficiency. Just how important a role is played by this newly recognized pathway of spread in natural transmission is, as of now, unclear and in need of further studies. Although it was not identified as a route of infection in epidemiological studies thus far, the worryingly high attack rate suggests that we would be well-advised to carefully avoid the inhalation of aerosols from prion-containing materials.


 Key words: prion, prion transmission, scrapie, chronic wasting diseases, CWD, Creutzfeldt-Jacob-disease, CJD, TSE, aerosol, pathogens, allergens Submitted: 05/19/11 Accepted: 06/09/11 DOI: 10.4161/pri.5.3.16851 *Correspondence to: Lothar Stitz or Adriano Aguzzi; Email: lothar.stitz@fli.bund.de or adriano.aguzzi@usz.ch


 References 1. Aguzzi A, Calella AM. Prions: protein aggregation and infectious diseases. Physiol Rev 2009; 89:1105-52. 2. Brown P, Gajdusek DC, Gibbs CJ Jr, Asher DM. Potential epidemic of Creutzfeldt-Jakob disease from human growth hormone therapy. N Engl J Med 1985; 313:728-31. 3. Kimberlin RH, Walker CA. Pathogenesis of mouse scrapie: dynamics of agent replication in spleen, spinal cord and brain after infection by different routes. J Comp Pathol 1979; 89:551-62. 4. Petsch B, Müller-Schiffmann A, Lehle A, Zirdum E, Prikulis I, Kuhn F, et al. Biological effects and use of PrPSc- and PrP-specific antibodies generated by immunizing with purified full length native mouse prions. J Virol 2011; 85:4538-46; PMID: 21345946. 5. Mulcahy ER, Bartz JC, Kincaid AE, Bessen RA. Prion infection of skeletal muscle cells and papillae in the tongue. J Virol 2004; 78:6792-8. 6. Glatzel M, Aguzzi A. PrP(C) expression in the peripheral nervous system is a determinant of prion neuroinvasion. J Gen Virol 2000; 81:2813-21. 7. Scott JR, Foster JD, Fraser H. Conjunctival instillation of scrapie in mice can produce disease. Vet Microbiol 1993; 34:305-9. 8. Kincade AE, Bartz JC. The nasal cavity is a route for prion infection in hamsters. J Virol 2007; 81:4482-91. 9. Klein MA, Frigg R, Flechsig E, Raeber AJ, Kalinke U, Bluethmann H, et al. A crucial role for B cells in neuroinvasive scrapie. Nature 1997; 390:687-90. 10. Klein MA, Kaeser PS, Schwarz P, Weyd H, Xenarios I, Zinkernagel RM, et al. Complement facilitates early prion pathogenesis. Nat Med 2001; 7:488-92. 11. Blättler T, Brandner S, Raeber AJ, Klein MA, Voigtländer T, Weissmann C, et al. PrP-expressing tissue required for transfer of scrapie infectivity from spleen to brain. Nature 1997; 389:69-73. 12. Raeber AJ, Sailer A, Hegyi I, et al. Ectopic expression of prion protein (PrP) in T lymphocytes or hepatocytes of PrP knockout mice is insufficient to sustain prion replication. Proc Natl Acad Sci USA 1999; 96:3987-92. 13. Klein MA, Frigg R, Raeber AJ, Flechsig E, Hegyi I, Zinkernagel RM, et al. PrP expression in B lymphocytes is not required for prion neuroinvasion. Nat Med 1998; 4:1429-33. 14. Raeber AJ, Klein MA, Frigg R, Flechsig E, Aguzzi A, Weissmann C, et al. PrP-dependent association of prions with splenic but not circulating lymphocytes of scrapie-infected mice. EMBO J 1999; 18:2702-6. 15. Montrasio F, Cozzio A, Flechsig E, Rossi D, Klein MA, Rülicke T, et al. B lymphocyte-restricted expression of prion protein does not enable prion replication in prion protein knockout mice. Proc Natl Acad Sci USA 2001; 98:4034-7. 16. Klein MA, Frigg R, Flechsig E, Raeber AJ, Kalinke U, Bluethmann H, et al. A crucial role for B cells in neuroinvasive scrapie. Nature 1997; 390:687-90. 17. Prinz M, Huber G, Macpherson AJ, Heppner FL, Glatzel M, Eugster HP, et al. Oral prion infection requires normal numbers of Peyer’s Patches but not of enteric lymphocytes. Am J Pathol 2003; 162:1103-11. 18. Prinz M, Montrasio F, Klein MA, Schwarz P, Priller J, Odermatt B, et al. Lymph nodal prion replication and neuroinvasion in mice devoid of follicular dendritic cells. Proc Natl Acad Sci USA 2002; 99:919-24.


 19. Klein MA, Kaeser PS, Schwarz P, Weyd H, Xenarios I, Zinkernagel RM, et al. Complement facilitates early prion pathogenesis. Nat Med 2001; 7:488-92. 20. Zabel MD, Heikenwalder M, Prinz M, Arrighi I, Schwarz P, Kranich J, et al. Stromal complement receptor CD21/35 facilitates lymphoid prion colonization and pathogenesis. J Immunol 2007; 179:6144-52. 21. Brown P, Gibbs CJ, Rodgers-Johnson P, Asher DM, Sulima MP, Bacote A, et al. Human spongiform encephalopathy: the National Institutes of Health series of 300 cases of experimentally transmitted disease. Ann Neurol 1994; 35:513-29. 22. Clarke MC, Haig DA. Presence of the transmissible agent of scrapie in the serum of affected mice and rats. Vet Rec 1967; 80:504. 23. Mathiason CK, Powers JG, Dahmes SJ, Osborn DA, Miller KV, Warren RJ, et al. Infectious prions in the saliva and blood of deer with chronic wasting disease. Science 2006; 314:133-6. 24. Lacroux C, Simon S, Benestad SL, Maillet S, Mathey J, Lugan S, et al. Prions in milk from ewes incubating natural scrapie. PLoS Pathog 2008; 4:1000238. 25. Seeger H, Heikenwalder M, Zeller N, Kranich J, Schwarz P, Gaspert A, et al. Coincident scrapie infection and nephritis lead to urinary prion excretion. Science 2005; 310:324-6. 26. Heikenwalder M, Kurrer MO, Margalith I, Kranich J, Zeller N, Haybaeck J, et al. Lymphotoxin-dependent prion replication in inflammatory stromal cells of granulomas. Immunity 2008; 29:998-1008. 27. Heikenwalder M, Zeller N, Seeger H, Prinz M, Klöhn PC, Schwarz P, et al. Chronic lymphocytic inflammation specifies the organ tropism of prions. Science 2005; 307:1107-10.


 28. Raabe OG, Yeh HC, Newton GJ, Phalen RF, Velasquez DJ. Deposition of inhaled monodisperse aerosols in small rodents. Inhaled Part 1975; 41:3-21. 29. Raabe OG, Al-Bayati MA, Teague SV, Rasolt A. Regional deposition of inhaled monodisperse coarse and fine aerosol particles in small laboratory animals. Ann Occup Hyg 1988; 32:53-63. 30. Haybaeck J, Heikenwalder M, Klevenz B, Schwarz P, Margalith I, Bridel C, et al. Aerosols transmit prions to immunocompetent and immunodeficient mice. PLoS Pathog 2011; 7:1001257. 31. Hainfellner JA, Jellinger K, Budka H. Testing for prion protein does not confirm previously reported conjugal CJD. Lancet 1996; 347:616-7. 32. Ligios C, Sigurdson CJ, Santucciu C, Carcassola G, Manco G, Basagni M, et al. PrP(Sc) in mammary glands of sheep affected by scrapie and mastitis. Nat Med 2005; 11:1137-8. 33. Denkers ND, Seelig DM, Telling GC, Hoover EA. Aerosol and nasal transmission of chronic wasting disease in cervidized mice. J Gen Virol 2010; 91:1651-8. 34. Nichols TA, Pulford B, Wyckoff AC, Meyerett C, Michel B, Gertig K, et al. Detection of protease-resistant cervid prion protein in water from a CWD-endemic area. Prion 2009; 3:171-83. 35. Llewelyn CA, Hewitt PE, Knight RS, Amar K, Cousens S, Mackenzie J, et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004; 363:417-21.


 36. Peden AH, Head MW, Ritchie DL, Bell JE, Ironside JW. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 2004; 364:527-9. 37. Adjemian JZ, Howell J, Holzbauer S, Harris J, Recuenco S, McQuiston J, et al. A clustering of immune-mediated polyradiculoneuropathy among swine abattoir workers exposed to aerosolized porcine brains, Indiana, United States. Int J Occup Environ Health 2009; 15:331-8. 38. Agrawal A, Singh SK, Singh VP, Murphy E, Parikh I. Partitioning of asal and pulmonary resistance changes during noninvasive plethysmography in mice. J Appl Physiol 2008; 105:1975-9. 39. Bates JH, Irvin CG. Measuring lung function in mice: the phenotyping uncertainty principle. J Appl Physiol 2003; 94:1297-306. 40. Zanusso G, Ferrari S, Cardone F, Zampieri P, Gelati M, Fiorini M, et al. Detection of pathologic prion protein in the olfactory epithelium in sporadic Creutzfeldt-Jakob disease. N Engl J Med 2003; 348:711-9. 41. Tabaton M, Monaco S, Cordone MP, Colucci M, Giaccone G, Tagliavini F, et al. Prion deposition in olfactory biopsy of sporadic Creutzfeldt-Jakob disease. Ann Neurol 2004; 55:294-6.


 PRION www.landesbioscience.com


 Prion 5:3, 138-141; July/August/September 2011; © 2011 Landes Bioscience




==============================




Accelerated shedding of prions following damage to the olfactory epithelium


Richard A. Bessen1,*, Jason M. Wilham2, Diana Lowe1, Christopher P. Watschke1, Harold Shearin1, Scott Martinka1, Byron Caughey2 and James A. Wiley1


+ Author Affiliations




1Department of Immunology and Infectious Diseases, Montana State University, Bozeman, Montana, USA 2Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute of Allergies and Infectious Diseases, Hamilton, Montana, USA


ABSTRACT


In this study we investigated the role of damage to the nasal mucosa in the shedding of prions into nasal fluids as a pathway for prion transmission. Here we demonstrate that prions can replicate to high levels in the olfactory sensory epithelium (OSE) in hamsters and that induction of apoptosis in olfactory receptor neurons (ORNs) in the OSE resulted in sloughing off of the OSE from nasal turbinates into the lumen of the nasal airway. In the absence of nasotoxic treatment olfactory marker protein (OMP), which is specific for ORNs, was not detected in nasal lavages. However, after nasotoxic treatment that leads to apoptosis of ORNs both OMP and prion proteins were present in nasal lavages. The cellular debris that was released from the OSE into the lumen of the nasal airway was positive for both OMP and the disease-specific isoform of the prion protein, PrPSc. Using the real time quaking-induced conversion assay to quantify prions, a 100- to 1,000-fold increase in prion seeding activity was observed in nasal lavages following nasotoxic treatment. Since neurons replicate prions to higher levels than other cell types and ORNs are the most environmentally exposed neurons, we propose that an increase in ORN apoptosis or damage to the nasal mucosa in a host with a pre-existing prion infection of the OSE could lead to a substantial increase in the release of prion infectivity into nasal fluids. This mechanism of prion shedding from the olfactory mucosa could contribute to prion transmission.








Aerosols Transmit Prions to Immunocompetent and Immunodeficient Mice


 Johannes Haybaeck1.¤a, Mathias Heikenwalder1.¤b, Britta Klevenz2., Petra Schwarz1, Ilan Margalith1, Claire Bridel1, Kirsten Mertz1,3, Elizabeta Zirdum2, Benjamin Petsch2, Thomas J. Fuchs4, Lothar Stitz2*, Adriano Aguzzi1* 1 Department of Pathology, Institute of Neuropathology, University Hospital Zurich, Zurich, Switzerland, 2 Institute of Immunology, Friedrich-Loeffler-Institut, Tu¨ bingen, Germany, 3 Department of Pathology, Clinical Pathology, University Hospital Zurich, Zurich, Switzerland, 4 Department of Computer Science, Machine Learning Laboratory, ETH Zurich, Zurich, Switzerland


 Abstract


 Prions, the agents causing transmissible spongiform encephalopathies, colonize the brain of hosts after oral, parenteral, intralingual, or even transdermal uptake. However, prions are not generally considered to be airborne. Here we report that inbred and crossbred wild-type mice, as well as tga20 transgenic mice overexpressing PrPC, efficiently develop scrapie upon exposure to aerosolized prions. NSE-PrP transgenic mice, which express PrPC selectively in neurons, were also susceptible to airborne prions. Aerogenic infection occurred also in mice lacking B- and T-lymphocytes, NK-cells, follicular dendritic cells or complement components. Brains of diseased mice contained PrPSc and transmitted scrapie when inoculated into further mice. We conclude that aerogenic exposure to prions is very efficacious and can lead to direct invasion of neural pathways without an obligatory replicative phase in lymphoid organs. This previously unappreciated risk for airborne prion transmission may warrant re-thinking on prion biosafety guidelines in research and diagnostic laboratories.


 SNIP...


 In summary, our results establish aerosols as a surprisingly efficient modality of prion transmission. This novel pathway of prion transmission is not only conceptually relevant for the field of prion research, but also highlights a hitherto unappreciated risk factor for laboratory personnel and personnel of the meat processing industry. In the light of these findings, it may be appropriate to revise current prion-related biosafety guidelines and health standards in diagnostic and scientific laboratories being potentially confronted with prion infected materials. While we did not investigate whether production of prion aerosols in nature suffices to cause horizontal prion transmission, the finding of prions in biological fluids such as saliva, urine and blood suggests that it may be worth testing this possibility in future studies.


 Citation: Haybaeck J, Heikenwalder M, Klevenz B, Schwarz P, Margalith I, et al. (2011) Aerosols Transmit Prions to Immunocompetent and Immunodeficient Mice. PLoS Pathog 7(1): e1001257. doi:10.1371/journal.ppat.1001257 Editor: David Westaway, University of Alberta, Canada Received March 22, 2010; Accepted December 13, 2010; Published January 13, 2011




PLEASE SEE FULL TEXT, AND AGAIN, many thanks to PLOS for open access !!!




http://www.plospathogens.org/article/info:doi/10.1371/journal.ppat.1001257





WHO Tables on Tissue Infectivity Distribution in Transmissible Spongiform Encephalopathies Updated 2010


 also in the references at bottom i saw ;


 12. A single positive marrow in multiple transmission attempts from cattle orally dosed with BSE-infected brain [Wells et al., 1999; Wells et al., 2005; Sohn et al., 2009].




http://www.who.int/bloodproducts/tablestissueinfectivity.pdf





snip... see full text ;




Thursday, December 22, 2011


 Risk of Prion Disease Transmission through Bovine-Derived Bone Substitutes: A Systematic Review Clin Implant Dent Relat Res. 2011 Dec 15. doi: 10.1111/j.1708-8208.2011.00407.x. [Epub ahead of print]




http://transmissiblespongiformencephalopathy.blogspot.com/2011/12/risk-of-prion-disease-transmission.html





Monday, January 17, 2011


 Aerosols Transmit Prions to Immunocompetent and Immunodeficient Mice




http://transmissiblespongiformencephalopathy.blogspot.com/2011/01/aerosols-transmit-prions-to.html





Monday, February 22, 2010


 Aerosol and Nasal Transmission of Chronic Wasting Disease in Cervidized Mice


 Published online ahead of print on 17 February 2010 as doi:10.1099/vir.0.017335-0 J Gen Virol (2010), DOI 10.1099/vir.0.017335-0 © 2010 Society for General Microbiology




http://chronic-wasting-disease.blogspot.com/2010/02/aerosol-and-nasal-transmission-of.html






 Friday, December 11, 2009






 CWD, FECES, ORAL LESIONS, Aerosol and intranasal transmission



 http://chronic-wasting-disease.blogspot.com/2009/12/cwd-feces-oral-lesions-aerosol-and.html








 2011 December Prion TSE update






 Monday, December 26, 2011




Prion Uptake in the Gut: Identification of the First Uptake and Replication Sites




http://transmissiblespongiformencephalopathy.blogspot.com/2011/12/prion-uptake-in-gut-identification-of.html






 Thursday, December 22, 2011


 Risk of Prion Disease Transmission through Bovine-Derived Bone Substitutes: A Systematic Review Clin Implant Dent Relat Res. 2011 Dec 15. doi: 10.1111/j.1708-8208.2011.00407.x. [Epub ahead of print]




http://transmissiblespongiformencephalopathy.blogspot.com/2011/12/risk-of-prion-disease-transmission.html






 Saturday, December 3, 2011


 Candidate Cell Substrates, Vaccine Production, and Transmissible Spongiform Encephalopathies


 Volume 17, Number 12—December 2011




http://transmissiblespongiformencephalopathy.blogspot.com/2011/12/candidate-cell-substrates-vaccine.html





Friday, December 23, 2011


 Oral Transmission of L-type Bovine Spongiform Encephalopathy in Primate Model


 Volume 18, Number 1—January 2012 Dispatch




http://transmissiblespongiformencephalopathy.blogspot.com/2011/12/oral-transmission-of-l-type-bovine.html





Tuesday, November 08, 2011


 Can Mortality Data Provide Reliable Indicators for Creutzfeldt-Jakob Disease Surveillance? A Study in France from 2000 to 2008 Vol. 37, No. 3-4, 2011


 Original Paper


 Conclusions:These findings raise doubt about the possibility of a reliable CJD surveillance only based on mortality data.




http://creutzfeldt-jakob-disease.blogspot.com/2011/11/can-mortality-data-provide-reliable.html




2006


 USA sporadic CJD cases rising ;


 There is a growing number of human CJD cases, and they were presented last week in San Francisco by Luigi Gambatti(?) from his CJD surveillance collection.


 He estimates that it may be up to 14 or 15 persons which display selectively SPRPSC and practically no detected RPRPSC proteins.




http://www.fda.gov/ohrms/dockets/ac/06/transcripts/1006-4240t1.htm




http://www.fda.gov/ohrms/dockets/ac/06/transcripts/2006-4240t1.pdf





2008 The statistical incidence of CJD cases in the United States has been revised to reflect that there is one case per 9000 in adults age 55 and older. Eighty-five percent of the cases are sporadic, meaning there is no known cause at present.




http://www.cjdfoundation.org/fact.html





CJD USA RISING, with UNKNOWN PHENOTYPE ;


 5 Includes 41 cases in which the diagnosis is pending, and 17 inconclusive cases;


 *** 6 Includes 46 cases with type determination pending in which the diagnosis of vCJD has been excluded.




http://www.cjdsurveillance.com/pdf/case-table.pdf






 Thursday, August 4, 2011





Terry Singeltary Sr. on the Creutzfeldt-Jakob Disease Public Health Crisis, Date aired: 27 Jun 2011 (SEE VIDEO)





http://transmissiblespongiformencephalopathy.blogspot.com/2011/08/terry-singeltary-sr-on-creutzfeldt.html






 Sunday, August 21, 2011


 The British disease, or a disease gone global, The TSE Prion Disease (SEE VIDEO)




http://transmissiblespongiformencephalopathy.blogspot.com/2011/08/british-disease-or-disease-gone-global.html





Saturday, March 5, 2011


 MAD COW ATYPICAL CJD PRION TSE CASES WITH CLASSIFICATIONS PENDING ON THE RISE IN NORTH AMERICA




http://transmissiblespongiformencephalopathy.blogspot.com/2011/03/mad-cow-atypical-cjd-prion-tse-cases.html





Thursday, December 8, 2011




S. Korea confirms second case of iatrogenic Creutzfeldt-Jakob disease 48-year-old man 2011/12/08 11:08 KST





http://usdavskorea.blogspot.com/2011/12/s-korea-confirms-second-case-of.html










 Thursday, December 08, 2011




A case of Iatrogenic Creutzfeldt Jakob Disease (iCJD) in a patient who had received a German-manufactured human dura mater graft 23 years ago





http://creutzfeldt-jakob-disease.blogspot.com/2011/12/case-of-iatrogenic-creutzfeldt-jakob.html





also, see incredible infection rate of TSE CWD on this game farm recently closed down. incredible. ...tss





Tuesday, December 20, 2011





CHRONIC WASTING DISEASE CWD WISCONSIN Almond Deer (Buckhorn Flats) Farm Update DECEMBER 2011





http://chronic-wasting-disease.blogspot.com/2011/12/chronic-wasting-disease-cwd-wisconsin.html






 EFSA Journal 2011 The European Response to BSE: A Success Story






 This is an interesting editorial about the Mad Cow Disease debacle, and it's ramifications that will continue to play out for decades to come ;










 Monday, October 10, 2011 EFSA Journal 2011 The European Response to BSE: A Success Story






 snip...






 EFSA and the European Centre for Disease Prevention and Control (ECDC) recently delivered a scientific opinion on any possible epidemiological or molecular association between TSEs in animals and humans (EFSA Panel on Biological Hazards (BIOHAZ) and ECDC, 2011). This opinion confirmed Classical BSE prions as the only TSE agents demonstrated to be zoonotic so far but the possibility that a small proportion of human cases so far classified as "sporadic" CJD are of zoonotic origin could not be excluded. Moreover, transmission experiments to non-human primates suggest that some TSE agents in addition to Classical BSE prions in cattle (namely L-type Atypical BSE, Classical BSE in sheep, transmissible mink encephalopathy (TME) and chronic wasting disease (CWD) agents) might have zoonotic potential.






 snip...






 http://www.efsa.europa.eu/en/efsajournal/pub/e991.htm?emt=1






 http://www.efsa.europa.eu/en/efsajournal/doc/e991.pdf









see follow-up here about North America BSE Mad Cow TSE prion risk factors, and the ever emerging strains of Transmissible Spongiform Encephalopathy in many species here in the USA, including humans ;






 http://transmissiblespongiformencephalopathy.blogspot.com/2011/10/efsa-journal-2011-european-response-to.html









Wednesday, June 15, 2011




Galveston, Texas - Isle port moves through thousands of heifers headed to Russia, none from Texas, Alabama, or Washington, due to BSE risk factor





http://transmissiblespongiformencephalopathy.blogspot.com/2011/06/galveston-texas-isle-port-moves-through.html








MAD COW DISEASE, TEXAS STYLE




http://www.organicconsumers.org/articles/article_23850.cfm









Wednesday, March 31, 2010





Atypical BSE in Cattle





To date the OIE/WAHO assumes that the human and animal health standards set out in the BSE chapter for classical BSE (C-Type) applies to all forms of BSE which include the H-type and L-type atypical forms. This assumption is scientifically not completely justified and accumulating evidence suggests that this may in fact not be the case. Molecular characterization and the spatial distribution pattern of histopathologic lesions and immunohistochemistry (IHC) signals are used to identify and characterize atypical BSE. Both the L-type and H-type atypical cases display significant differences in the conformation and spatial accumulation of the disease associated prion protein (PrPSc) in brains of afflicted cattle. Transmission studies in bovine transgenic and wild type mouse models support that the atypical BSE types might be unique strains because they have different incubation times and lesion profiles when compared to C-type BSE. When L-type BSE was inoculated into ovine transgenic mice and Syrian hamster the resulting molecular fingerprint had changed, either in the first or a subsequent passage, from L-type into C-type BSE.


 In addition, non-human primates are specifically susceptible for atypical BSE as demonstrated by an approximately 50% shortened incubation time for L-type BSE as compared to C-type. Considering the current scientific information available, it cannot be assumed that these different BSE types pose the same human health risks as C-type BSE or that these risks are mitigated by the same protective measures.





This study will contribute to a correct definition of specified risk material (SRM) in atypical BSE. The incumbent of this position will develop new and transfer existing, ultra-sensitive methods for the detection of atypical BSE in tissue of experimentally infected cattle.





http://www.prionetcanada.ca/detail.aspx?menu=5&dt=293380&app=93&cat1=387&tp=20&lk=no&cat2








Thursday, August 12, 2010




Seven main threats for the future linked to prions




First threat




The TSE road map defining the evolution of European policy for protection against prion diseases is based on a certain numbers of hypotheses some of which may turn out to be erroneous. In particular, a form of BSE (called atypical Bovine Spongiform Encephalopathy), recently identified by systematic testing in aged cattle without clinical signs, may be the origin of classical BSE and thus potentially constitute a reservoir, which may be impossible to eradicate if a sporadic origin is confirmed.




***Also, a link is suspected between atypical BSE and some apparently sporadic cases of Creutzfeldt-Jakob disease in humans. These atypical BSE cases constitute an unforeseen first threat that could sharply modify the European approach to prion diseases.




Second threat




snip...




http://www.neuroprion.org/en/np-neuroprion.html








Saturday, November 19, 2011





Novel Prion Protein in BSE-affected Cattle, Switzerland





http://transmissiblespongiformencephalopathy.blogspot.com/2011/11/novel-prion-protein-in-bse-affected.html








Price of PRION TSE aka MAD COW POKER GOES UP $$$

 Saturday, December 3, 2011



Isolation of Prion with BSE Properties from Farmed Goat Volume 17, Number 12—December 2011

http://transmissiblespongiformencephalopathy.blogspot.com/2011/12/isolation-of-prion-with-bse-properties.html


Saturday, June 25, 2011

Transmissibility of BSE-L and Cattle-Adapted TME Prion Strain to Cynomolgus Macaque

 "BSE-L in North America may have existed for decades"

 http://transmissiblespongiformencephalopathy.blogspot.com/2011/06/transmissibility-of-bse-l-and-cattle.html


Over the next 8-10 weeks, approximately 40% of all the adult mink on the farm died from TME.

snip...

The rancher was a ''dead stock'' feeder using mostly (>95%) downer or dead dairy cattle...

 http://web.archive.org/web/20030516051623/http://www.bseinquiry.gov.uk/files/mb/m09/tab05.pdf


2010-2011

When L-type BSE was inoculated into ovine transgenic mice and Syrian hamster the resulting molecular fingerprint had changed, either in the first or a subsequent passage, from L-type into C-type BSE. In addition, non-human primates are specifically susceptible for atypical BSE as demonstrated by an approximately 50% shortened incubation time for L-type BSE as compared to C-type. Considering the current scientific information available, it cannot be assumed that these different BSE types pose the same human health risks as C-type BSE or that these risks are mitigated by the same protective measures. This study will contribute to a correct definition of specified risk material (SRM) in atypical BSE. The incumbent of this position will develop new and transfer existing, ultra-sensitive methods for the detection of atypical BSE in tissue of experimentally infected cattle.

 http://www.prionetcanada.ca/detail.aspx?menu=5&dt=293380&app=93&cat1=387&tp=20&lk=no&cat2

Friday, December 23, 2011




Oral Transmission of L-type Bovine Spongiform Encephalopathy in Primate Model


 Volume 18, Number 1—January 2012 Dispatch






http://transmissiblespongiformencephalopathy.blogspot.com/2011/12/oral-transmission-of-l-type-bovine.html



 2011 Monday, September 26, 2011

L-BSE BASE prion and atypical sporadic CJD

http://bse-atypical.blogspot.com/2011/09/l-bse-base-prion-and-atypical-sporadic.html


SEE RISE OF SPORADIC CJD YEAR TO YEAR ;

http://www.cjd.ed.ac.uk/figures.htm

 TSS

Wednesday, December 28, 2011

FDA Targets Risks From Reused Devices

FDA Targets Risks From Reused Devices


Some medical devices are reused many times in common surgical and diagnostic procedures, and have been for years. They include instruments used in surgery (like clamps and forceps), and endoscopes (like bronchoscopes and colonoscopes) used to visualize areas inside the body.


And the Food and Drug Administration (FDA) wants to ensure that they are safely reused.


The agency is working with healthcare providers, manufacturers, organizations that set standards, and other government agencies to reduce the risk of infection from the inadequate “reprocessing” of these durable devices designed for repeated use. Reprocessing means cleaning and high-level disinfection or sterilization.


FDA has received reports of patients being exposed to microscopic amounts of blood, body fluids and tissue from other patients that may have occurred because the reusable devices were inadequately reprocessed and these contaminants were not removed. Transmission of infection was extremely rare, but the potential for becoming infected by an inadequately processed device was there.


So if you’re scheduled to have a medical procedure, how worried should you be about this?


Not worried enough to cancel or delay your plans, says FDA.


The risk of acquiring an infection from a reprocessed medical device is low, says William Maisel, MD, deputy director for science at the FDA's Center for Devices and Radiological Health. The benefits of these procedures in diagnosing and treating medical conditions far outweigh any risk, he says.


That said, there are questions you can ask your healthcare providers.


Frank Nemec, MD, a Las Vegas gastroenterologist and patient advocate who spoke at an FDA-sponsored workshop in June, advises his patients to ask this question: What precautions are in place to ensure that the procedure will be done safely?


One person who did ask that question is Pamela D. Scott, a biomedical engineer who has been working on this issue at FDA.


Earlier this year, Scott’s mother, Ophelia, was about to have a colonoscopy. Scott called the gastro-intestinal clinic and asked to speak to the person in charge of reprocessing medical devices. In this case, it was the head nurse.


Scott asked if the clinic staff was aware of news reports about problems with the reprocessing of endoscopes. And, if they were aware, how did these reports affect how they clean and disinfect these tools?


The nurse replied that clinic had recently assessed its reprocessing procedures and called in the manufacturer to make sure staff members are properly cleaning and disinfecting or sterilizing the devices.


“Just to know that they took steps, that they had procedures, that helped me,” Scott says.


So ask questions, just as Nemec recommends and Scott did on her mother’s behalf. Before having any medical procedure, it’s a good idea to learn more about the procedure and steps the healthcare facility takes to keep patients safe.


Health care providers are one source of this information. Many professional organizations, including the American Academy of Family Physicians, offer advice on how to ask such questions of your healthcare provider.


FDA is working with manufacturers and healthcare providers to:


Make sure that the makers of these devices are providing reprocessing instructions that are clear and scientifically validated.


Make sure that staff at hospitals and other healthcare facilities understand and are following the manufacturers’ instructions.


Identify device designs that facilitate optimal cleaning, disinfecting and sterilization.


And FDA has created a new website (www.fda.gov/reprocessingreusabledevices) with information about these medical tools.


To report a problem, the site also provides a link to MedWatch, the FDA Safety Information and Adverse Event Reporting Program.


This article appears on FDA's Consumer Updates page, which features the latest on all FDA-regulated products.


Posted December 28, 2011








2002


Date submitted: 3 Jun 2002


>> eLetter ID: gutjnl_el;21


>> >> Gut eLetter for Bramble and Ironside 50 (6): 888


>> >>Name: Terry S. Singeltary Sr.


>>Email: flounder@wt.net


>>Title/position: disabled {neck injury}


>>Place of work: CJD WATCH


>>IP address: 216.119.162.85


>>Hostname: 216-119-162-85.ipset44.wt.net


>>Browser: Mozilla/5.0 (Windows; U; Win98; en-US; rv:0.9.4)


>>Gecko/20011019 Netscape6/6.2


>> >>Parent ID: 50/6/888


>>Citation:


>> Creutzfeldt-Jakob disease: implications for gastroenterology


>> M G Bramble and J W Ironside


>> Gut 2002; 50: 888-890 (Occasional viewpoint)






>>-----------------------------------------------------------------


>>"CJDs (all human TSEs) and Endoscopy Equipment"


>>----------------------------------------------------------------- >> >> >>


>>regarding your article;


>>


>> Creutzfeldt-Jakob disease: implications for gastroenterology >>


>>I belong to several support groups for victims and relatives


>>of CJDs. Several years ago, I did a survey regarding


>>endoscopy equipment and how many victims of CJDs have


>>had any type of this procedure done. To my surprise, many


>>victims had some kind of endoscopy work done on them.


>>As this may not be a smoking gun, I think it should


>>warrant a 'red flag' of sorts, especially since data now


>>suggests a substantial TSE infectivity in the gut wall


>>of species infected with TSEs. If such transmissions


>>occur, the ramifications of spreading TSEs from


>>endoscopy equipment to the general public would be


>>horrible, and could potential amplify the transmission


>>of TSEs through other surgical procedures in that


>>persons life, due to long incubation and sub-clinical


>>infection. Science to date, has well established


>>transmission of sporadic CJDs with medical/surgical


>>procedures.


Terry S. Singeltary Sr. >>CJD WATCH


Again, many thanks, Kindest regards,


Terry S. Singeltary Sr. P.O. Box 42 Bacliff, Texas USA 77518 flounder@wt.net CJD WATCH


[scroll down past article for my comments]


snip...




========================================================


Greetings List Members,


This is _very_ disturbing to me:


snip...


The distribution of PrPSc in the body is different in sporadic and variant CJD, reflecting the different pathogenesis of the two forms. In the case ot sporadic CJD, prion infectivity is largely limited to the CNS (including the retina) and only operations involving the brain and eye have resulted in iatrogenic transmission of the disease. Gastro-intestinal endoscopy is unlikely to be a vector for the transmission of sporadic CJD as infected tissue is not encountered during the procedure. No special precautions are necessary during or after the procedure and the endoscope should be cleaned and disinfected in the normal thorough way.4


snip...


i personally believe it is irresponsible for anyone to state in this day and time, that sporadic CJDs (now at 6 variants) will not transmit the disease by this route. considering infective dose cannot be quantified, only speculated, such a statement is thus, irresponsible. to hypothosize that sporadic CJD just happens spontaneously (with no scientific proof), that the PrPSc distribution in tissues of all sporadic CJDs is entirely different than that of vCJD, without being able to quantify the titre of infection, or even confirm all the different variants yet, again is _not_ based on all scientific data, then it's only a hypothosis. who is to say that some of these variants of sporadic CJD were not obtained _orally_?


also stated:


snip...


Although thorough cleaning of flexible endoscopes ensures patient safety for ''normal'' pathogens, the same process may not be adequate for the PrPSc.


snip...


The sporadic form of CJD affects approximately one person per mil-lion per annum in the population on a worldwide basis.


who is to say how much infectivity are in some of these variants of sporadic CJDs, without confirming this? if we look at the 6 different variants of sporadic CJDs, has the infective dose for all 6 _documented_ variants been quantified, and documented as being 'measurable'?


will there be more variants of sporadic CJDs, and what of the ramifications from them?


what of other strains/variants of TSE in cattle, BSE in sheep, CWD in cattle, or any of the 20+ strains of Scrapies in deer/elk? i get dizzy thinking of the different scenerio's. what would the human TSEs from these species look like and how can anyone quantify any tissue infectivity from these potential TSE transmissions to humans, and the risk scenerio described here from this potential route? could not some of these sporadic CJDs have derived directly or indirectly from one of these species, and if so, pose a risk by the route described here?


something else to consider, in the recent finding of the incubation period of 38 years from a _small_ dose of human growth hormone;


snip...


We describe the second patient with hGH related CJD in the Netherlands. The patient developed the disease 38 years after hGH injections. To our knowledge, this is the longest incubation period described for any form of iatrogentic CJD. Furthermore, our patient was _not_ treated with hGH, but only received a _low_ dose as part of a diagnostic procedure. (see full text below).


snip...


so my quesion is, how low is 'low' in quantifing the infectious dose in vCJD, comparing to _all_ sporadic CJDs, from the different potential routes, sources, and infectivity dose?


will the titre of infectivity in every tissue and organ of all sporadic CJDs stay exact or constant, no matter what the infective dose, route and species may be? this is considering you don't buy the fact that sporadic CJDs 85%+ of _all_ CJDs, are a happen stance of bad luck, happen spontaneously without cause, and are one-in-a-million world wide, with no substantial surveillance to confirm this.


Diagnosis and Reporting of Creutzfeldt-Jakob Disease T. S. Singeltary, Sr; D. E. Kraemer; R. V. Gibbons, R. C. Holman, E. D. Belay, L. B. Schonberger




and what of Dr. Prusiner et al recent work about tissue infectivity;


Prions in skeletal muscle


snip...


Our data demonstrate that factors in addition to the amount of PrP expressed determine the tropism of prions for certain tissues. That some muscles are intrinsically capable of accumulating substantial titers of prions is of particular concern. Because significant dietary exposure to prions might occur through the consumption of meat, even if it is largely free of neural and lymphatic tissue, a comprehensive effort to map the distribution of prions in the muscle of infected livestock is needed. Furthermore, muscle may provide a readily biopsied tissue from which to diagnose prion disease in asymptomatic animals and even humans.


snip...






can the science/diagnostic measures used to date, measure this, and at the same time guarantee that no titre of infectivity exists from sporadic CJDs (all of the variants), from this potential mode and route of transmission?


i don't think so, this is just my opinion. this is why i get paid nothing, and these scientists get the big bucks. i just hope i am wrong and the big bucks are correct in their _hypothisis_ of this potential mode/route of transmission with endoscopy equipment, from _all_ human TSEs.


i understand we have to weigh the risks of what we know to what we don't know, to the disease we _may_ catch to what we are having the procedure for, but to categorically state at this present time of scientific knowledge;


snip...


"Gastro-intestinal endoscopy is unlikely to be a vector for the transmission of sporadic CJD as infected tissue is not encountered during the procedure. No special precautions are necessary during or after the procedure and the endoscope should be cleaned and disinfected in the normal thorough way.4"


snip...


but, to categorically state this, in my opinion, is not only wrong, but potentially very dangerous to the future of human health...TSS


SHORT REPORT


Creutzfeldt-Jakob disease 38 years after diagnostic use of human growth hormone


E A Croes, G Roks, G H Jansen, P C G Nijssen, C M van Duijn ...............................................................


J Neurol Neurosurg Psychiatry 2002;72:792-793


A 47 year old man is described who developed pathology proven Creutzfeldt-Jakob disease (CJD) 38 years after receiving a low dose of human derived growth hormone (hGH) as part of a diagnostic procedure. The patient presented with a cerebellar syndrome, which is compatible with iatrogenic CJD. This is the longest incubation period described so far for iatrogenic CJD. Furthermore, this is the first report of CJD after diagnostic use of hGH. Since the patient was one of the first in the world to receive hGH, other cases of iatrogenic CJD can be expected in the coming years.


Prion diseases are potentially transmissible. Human to human transmission was first reported in 1974, when a 55 year old woman was described who developed symptoms of Creutzfeldt-Jakob disease (CJD) 18 months after a corneal transplant.1 Since then, transmission has been reported after stereotactic electroencephalographic (EEG) depth recording, human growth hormone (hGH) and gonadotrophin treatment, and dura mater transplantation.2-5 More than 267 patients with iatrogenic CJD are known today and their number is growing.6 The most important iatrogenic cause of CJD is still contaminated cadaveric hGH. Exposure to contaminated hGH occurred before 1985, when recombinant growth hormone became available. In a recent study, incubation periods in 139 patients with hGH associated CJD were found to range from 5-30 years, with a median of 12 years.6 One of the factors influencing incubation time is genotype on polymorphic codon 129 of the prion protein gene.7 The incubation time is significantly shorter in people who are homozygous for either methionine or valine on this polymorphism.7


We describe the second patient with hGH related CJD in the Netherlands. The patient developed the disease 38 years after hGH injections. To our knowledge, this is the longest incubation period described for any form of iatrogenic CJD. Further-more, our patient was not treated with hGH but only received a low dose as part of a diagnostic procedure.


CASE REPORT


This patient presented at the age of 47 years with paraesthesia in both arms for six months, difficulty with walking for four weeks, and involuntary movements of mainly the upper extremities of two weeks' duration. He did not notice any change in cognitive function, although his twin sister had noticed minor memory disturbances. There was no family history of neurological disease. During childhood the patient had experienced a growth delay compared with his twin sister and with the average in the Netherlands. When he was 9 years old, a nitrogen retention test with 6 IU hGH over five days was performed to exclude growth hormone deficiency. Since the result was not decisive, a quantitative amino acid test was performed, which measures 30 amino acids during fasting and one, two, and three hours after growth hormone injection. No abnormal amino acid concentrations were found making the diagnosis of primordial dwarfism most likely. Therefore, no treatment with hGH was given.


On neurological examination we found a slight dysarthria without aphasia. Cranial nerve function was normal. Walking was unstable and wide based. During movements of the upper extremities myoclonic jerks were present. Sensation, muscle tone, and strength were normal. Co-ordination was impaired in all four limbs with a disturbed balance. Tendon reflexes were brisk at the arms and increased at the legs with a clonus in the ankle reflex. Plantar responses were both normal. On the mini mental state examination, the patient scored 30/30. Routine laboratory investigation, thyroid function, vitamin concentrations (B-1, B-6, B-12, and E), and copper metabolism were normal. Admission EEG examination showed generalised arrhythmic slow activity with diffuse spikes and spike waves. EEG examination two months later showed a further slowing of the rhythm with bilateral diphasic sharp waves but was not typical for CJD. Cerebral magnetic resonance imaging was normal. Cerebrospinal fluid examination showed 1 cell/3 µl, normal glucose and protein concentrations, and a strongly positive 14-3-3 protein test. The patient was homozygous for methionine on the PRNP codon 129 polymorphism. On clinical grounds, CJD was diagnosed. Within one month the patient's condition deteriorated rapidly and because of severe disturbances in coordination and progressive myoclonus he became bedridden. An eye movement disorder developed with slow saccadic and dysmetric eye movements. Temperature became unstable with peaks of 39°C without an infectious focus, for which a disorder of autoregulation was presumed. Until a very advanced stage, cognitive function was intact. The patient died five months after admission. The diagnosis of CJD was confirmed at necropsy. The brain weighed 990 g and showed clear cortical and cerebellar atrophy. Spongiosis, neuronal loss, and gliosis were found predominantly in the putamen, caudate nucleus, and basotemporal and cerebellar cortex; the cerebellum was the most severely affected of these. Vacuoles ranged from 2-12 µm. No amyloid or Kuru plaques were found. Immunohistochemical staining (3F4 antibody 1:1000, Senetek, USA) was clearly positive for prion protein accumulation in a "synaptic" distribution. Most deposition was found in the stratum moleculare of the cerebellum.


DISCUSSION


We describe a 47 year old patient who developed pathology proven CJD 38 years after hGH injections. The patient was never treated with hGH but received a small dose as part of a diagnostic procedure. The onset of CJD was signalled by prodromal symptoms of paraesthesia followed by a rapidly progressive ataxia. The disease presentation and course with predominantly cerebellar and eye movement disorders are compatible with iatrogenic CJD caused by hGH treatment.6 8


Growth hormone treatment was first described in 1958 but hGH was not produced on a larger scale from human pituitary glands until the beginning of the 1960s. In the Netherlands growth hormone extraction started in 1963 and was soon centrally coordinated. Until 1979 growth hormone was extracted non-commercially from pituitaries by a pharmaceutical company. In 1971 commercial products also became available. Our patient was one of the first to receive hGH in the Netherlands but the origin of this product was not recorded. A causal relation can therefore not be established with full certainty, but coincidentally receiving growth hormone and developing this very rare disease is unlikely. Since the clinical course in this relatively young patient is in accordance with an iatrogenic cause, we think the probability is high that the hGH injections explain the development of CJD in this patient.


The first Dutch patient with hGH related CJD died in 1990. 9 During several periods from 1963 to 1969 she received intramuscular injections of hGH. During an unknown period the hGH was derived from South America. At age 39, 27 years after starting the treatment, she developed an ataxic gait, slurred speech, sensory disorders, and myoclonus, but her cognitive function remained normal. Postmortem examination of the brain confirmed the diagnosis of CJD.9 Following the identification of this patient, a retrospective study was started to trace all 564 registered hGH recipients who were treated before May 1985. Until January 1995, none of these was suspected of having CJD.10 Since 1993 prospective surveillance for all forms of human prion disease has been carried out in the Netherlands and, apart from the patient described above, a further two patients with iatrogenic CJD have been identified, who developed the disease after dura mater transplantation.11


An incubation period as long as 38 years had never been reported for iatrogenic CJD. Huillard d'Aignaux et al7 studied the incubation period in 55 patients with hGH related CJD in a cohort of 1361 French hGH recipients. The median incubation period was between 9 and 10 years. Under the most pessimistic model, the upper limit of the 95% confidence interval varied between 17 and 20 years. Although the infecting dose cannot be quantified, it can be speculated that the long incubation period in our patient is partly explained by the administration of a limited amount of hGH. This hypothesis is supported by experimental models, in which higher infecting doses usually produce shorter incubation periods.6 Since our patient was one of the first in the world to receive hGH, this case indicates that still more patients with iatrogenic CJD can be expected in the coming years. Another implication of our study is that CJD can develop even after a low dose of hGH. This case once more testifies that worldwide close monitoring of any form of iatrogenic CJD is mandatory.


ACKNOWLEDGEMENTS


We are grateful to M Jansen PhD MD for his search for the origin of the growth hormone and P P Taminiau MD. CJD surveillance in the Netherlands is carried out as part of the EU Concerted Action on the Epidemiology of CJD and the the EU Concerted Action on Neuropathology of CJD, both funded through the BIOMED II programme, and is supported by the Dutch Ministry of Health. This surveillance would not have been possible without the cooperation of all Dutch neurologists and geriatricians.


........................................




Authors' affiliations


E A Croes, G Roks*, C M van Duijn, Genetic Epidemiology Unit, Department of Epidemiology and Biostatistics, Erasmus University Medical Centre Rotterdam, PO Box 1738, 3000 DR Rotterdam, Netherlands


P C G Nijssen, Department of Neurology, St Elisabeth Hospital, PO Box 90151, 5000 LC Tilburg, Netherlands


G H Jansen, Department of Pathology, University Medical Centre Utrecht, Heidelberglaan 100, 3584 CX Utrecht, Netherlands


*Also the Department of Neurology, St Elisabeth Hospital


Correspondence to: Professor C M van Duijn, Genetic Epidemiology Unit, Department of Epidemiology and Biostatistics, Erasmus University Medical Centre Rotterdam, PO Box 1738, 3000 DR Rotterdam, Netherlands; vanduijn@epib.fgg.eur.nl


Received 27 December 2001 In revised form 1 March 2002 Accepted 12 March 2002


Competing interests: none declared


REFERENCES


1 Duffy P, Wolf J, Collins G, et al. Possible person-to-person transmission of Creutzfeldt-Jakob disease. N Engl J Med 1974;290:692-3.


2 Bernoulli C, Siegfried J, Baumgartner G, et al. Danger of accidental person-to-person transmission of Creutzfeldt-Jakob disease by surgery. Lancet 1977;i:478-9.


3 Koch TK, Berg BO, De Armond SJ, et al. Creutzfeldt-Jakob disease in a young adult with idiopathic hypopituitarism: possible relation to the administration of cadaveric human growth hormone. N Engl J Med 1985;313:731-3.


4 Cochius JI, Burns RJ, Blumbergs PC, et al. Creutzfeldt-Jakob disease in a recipient of human pituitary-derived gonadotrophin. Aust NZ J Med 1990;20:592-3.


5 Thadani V, Penar PL, Partington J, et al. Creutzfeldt-Jakob disease probably acquired from a cadaveric dura mater graft: case report. J Neurosurg 1988;69:766-9.


6 Brown P, Preece M, Brandel JP, et al. Iatrogenic Creutzfeldt-Jakob disease at the millennium. Neurology 2000;55:1075-81.


7 Huillard d'Aignaux J, Costagliola D, Maccario J, et al. Incubation period of Creutzfeldt-Jakob disease in human growth hormone recipients in France. Neurology 1999;53:1197-201.


8 Billette de Villemeur T, Deslys JP, Pradel A, et al. Creutzfeldt-Jakob disease from contaminated growth hormone extracts in France. Neurology 1996;47:690-5.


9 Roos RA, Wintzen AR, Will RG, et al. Een patiënt met de ziekte van Creutzfeldt-Jakob na behandeling met humaan groeihormoon. Ned Tijdschr Geneeskd 1996;140:1190-3.


10 Wientjens DP, Rikken B, Wit JM, et al. A nationwide cohort study on Creutzfeldt-Jakob disease among human growth hormone recipients. Neuroepidemiology 2000;19:201-5.


11 Croes EA, Jansen GH, Lemstra AF, et al. The first two patients with dura mater associated Creutzfeldt-Jakob disease in the Netherlands. J Neurol 2001;248:877-81.


re-CJD after diagnostic use of human growth hormone


from a donor sourcing aspect, seems the record keeping here has a lot to be desired for, let us hope it has improved for recipients sake.


also, they speak of 'low dose fitting long incubation'. what about KURU still existing after some 40 years exposure had ceased. i don't believe in most instances the dose with kuru is low. just something else to ponder?


TSS






1: Ann Neurol 1999 Aug;46(2):224-33


Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects.


Division of Neuropathology, Institute of Pathology, Case Western Reserve University, Cleveland, OH 44106, USA.


snip...


The present data demonstrate the existence of six phenotypic variants of sCJD. The physicochemical properties of PrP(Sc) in conjunction with the PRNP codon 129 genotype largely determine this phenotypic variability, and allow a molecular classification of the disease variants.


snip...






were not all CJDs, even nvCJD, just sporadic, until proven otherwise?


Terry S. Singeltary Sr., P.O. BOX 42, Bacliff, Texas 77518 USA




Professor Michael Farthing wrote:


Louise Send this to Bramble (author) for a comment before we post. Michael


snip...see full text ;




Saturday, January 16, 2010


Evidence For CJD TSE Transmission Via Endoscopes 1-24-3 re-Singeltary to Bramble et al


Evidence For CJD/TSE Transmission Via Endoscopes


From Terry S. Singletary, Sr flounder@wt.net 1-24-3




snip...please see full text ;


2011


Monday, December 26, 2011


Prion Uptake in the Gut: Identification of the First Uptake and Replication Sites




Friday, December 23, 2011


Oral Transmission of L-type Bovine Spongiform Encephalopathy in Primate Model


Volume 18, Number 1—January 2012 Dispatch






Thursday, December 22, 2011


Risk of Prion Disease Transmission through Bovine-Derived Bone Substitutes: A Systematic Review Clin Implant Dent Relat Res. 2011 Dec 15. doi: 10.1111/j.1708-8208.2011.00407.x. [Epub ahead of print]






Saturday, December 3, 2011


Candidate Cell Substrates, Vaccine Production, and Transmissible Spongiform Encephalopathies


Volume 17, Number 12—December 2011






Monday, December 12, 2011


Second iatrogenic CJD case confirmed Korea






2011 Monday, September 26, 2011


L-BSE BASE prion and atypical sporadic CJD






Tuesday, November 08, 2011


Can Mortality Data Provide Reliable Indicators for Creutzfeldt-Jakob Disease Surveillance?


A Study in France from 2000 to 2008 Vol. 37, No. 3-4, 2011


Original Paper


Conclusions:These findings raise doubt about the possibility of a reliable CJD surveillance only based on mortality data.






FC5.1.1


Transmission Results in Squirrel Monkeys Inoculated with Human sCJD, vCJD, and GSS Blood Specimens: the Baxter Study


Brown, P1; Gibson, S2; Williams, L3; Ironside, J4; Will, R4; Kreil, T5; Abee, C3 1Fondation Alliance BioSecure, France; 2University of South Alabama, USA; 3University of Texas MD Anderson Cancer Center, USA; 4Western General Hospital, UK; 5Baxter BioSience, Austria


Background: Rodent and sheep models of Transmissible Spongiform Encephalopathy (TSE) have documented blood infectivity in both the pre-clinical and clinical phases of disease. Results in a (presumably more appropriate) non-human primate model have not been reported.


Objective: To determine if blood components (red cells, white cells, platelets, and plasma) from various forms of human TSE are infectious.


Methods: Blood components were inoculated intra-cerebrally (0.1 ml) and intravenously (0.5 ml) into squirrel monkeys from 2 patients with sporadic Creutzfeldt- Jakob disease (sCJD) and 3 patients with variant Creutzfeldt-Jakob disease (vCJD). Additional monkeys were inoculated with buffy coat or plasma samples from chimpanzees infected with either sCJD or Gerstmann-Sträussler-Scheinker disease (GSS). Animals were monitored for a period of 5 years, and all dying or sacrificed animals had post-mortem neuropathological examinations and Western blots to determine the presence or absence of the misfolded prion protein (PrPTSE).


Results: No transmissions occurred in any of the animals inoculated with blood components from patients with sporadic or variant CJD. All donor chimpanzees (sCJD and GSS) became symptomatic within 6 weeks of their pre-clinical phase plasmapheresis, several months earlier than the expected onset of illness. One monkey inoculated with purified leukocytes from a pre-clinical GSS chimpanzee developed disease after 36 months.


Conclusion: No infectivity was found in small volumes of blood components from 4 patients with sporadic CJD and 3 patients with variant CJD. ***However, a single transmission from a chimpanzee-passaged strain of GSS shows that infectivity may be present in leukocytes, and the shock of general anaesthesia and plasmspheresis appears to have triggered the onset of illness in pre-clinical donor chimpanzees.


Saturday, September 5, 2009


TSEAC MEETING FEBRUARY 12, 2004 THE BAXTER STUDY GSS


snip...




Wednesday, June 29, 2011


TSEAC Meeting August 1, 2011 donor deferral Saudi Arabia vCJD risk blood and blood products






Wednesday, August 24, 2011


All Clinically-Relevant Blood Components Transmit Prion Disease following a Single Blood Transfusion: A Sheep Model of vCJD




Wednesday, August 24, 2011


There Is No Safe Dose of Prions






layperson


Terry S. Singeltary Sr. P.O. Box 42 Bacliff, Texas USA 77518